,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2007', 'fs': 'Oct 2007', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwD2AS'}, 'Id': 'a0POZ000004AlwD2AS', 'Event_Date__c': '2007-10-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Oct 2007', 'Status_History__c': 'a132P000000ApEHQA0'}, 'change': None}]",Oct 2007,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2008', 'fs': 'May 2008', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2008.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2008.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwE2AS'}, 'Id': 'a0POZ000004AlwE2AS', 'Event_Date__c': '2008-05-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2008.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'May 2008', 'Status_History__c': 'a132P000000ApIEQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2008-11.pdf "" target=""_blank"">Special Foods Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2008-11.pdf "" target=""_blank"">Special Foods Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2008', 'fs': 'Nov 2008', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Friday 21 November 2008.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Friday 21 November 2008.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwF2AS'}, 'Id': 'a0POZ000004AlwF2AS', 'Event_Date__c': '2008-11-21', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Friday 21 November 2008.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2008-11.pdf "" target=""_blank"">Special Foods Subcommittee minutes</a>', 'Outcome__c': 'Recommended alteration to access criteria', 'Formatted_Date__c': 'Nov 2008', 'Status_History__c': 'a132P000000ApMpQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2009', 'fs': 'May 2009', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwG2AS'}, 'Id': 'a0POZ000004AlwG2AS', 'Event_Date__c': '2009-05-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Recommended alteration to access criteria', 'Formatted_Date__c': 'May 2009', 'Status_History__c': 'a132P000000ApQaQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2010', 'fs': 'May 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Friday 21 May 2010.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Friday 21 May 2010.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwH2AS'}, 'Id': 'a0POZ000004AlwH2AS', 'Event_Date__c': '2010-05-21', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Friday 21 May 2010.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'May 2010', 'Status_History__c': 'a132P000000ApaqQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2010', 'fs': 'Nov 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwI2AS'}, 'Id': 'a0POZ000004AlwI2AS', 'Event_Date__c': '2010-11-04', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Nov 2010', 'Status_History__c': 'a132P000000ApgtQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2012-09.pdf "" target=""_blank"">Special Foods Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2012-09.pdf "" target=""_blank"">Special Foods Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2012', 'fs': 'Sep 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 26 September 2012.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 26 September 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwK2AS'}, 'Id': 'a0POZ000004AlwK2AS', 'Event_Date__c': '2012-09-26', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Wednesday 26 September 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2012-09.pdf "" target=""_blank"">Special Foods Subcommittee minutes</a>', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'Sep 2012', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Aq9YQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwL2AS'}, 'Id': 'a0POZ000004AlwL2AS', 'Event_Date__c': '2013-05-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqPEQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Special Foods Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Special Foods Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2013', 'fs': 'Dec 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Thursday 5 December 2013.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Thursday 5 December 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwM2AS'}, 'Id': 'a0POZ000004AlwM2AS', 'Event_Date__c': '2013-12-05', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Thursday 5 December 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Special Foods Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Dec 2013', 'Status_History__c': 'a132P000000AqYoQAK'}, 'change': None}, {'Summary': {'s': 'PTAC accepted the Subcommittee recommendations on thickeners. PTAC recommended that patients who are currently receiving subsidised food/fluid thickener via Special Authority for use in the community continue to receive subsidised food/fluid thickener should they wish to continue using it.', 'fs': 'PTAC accepted the Subcommittee recommendations on thickeners. PTAC recommended that patients who are currently receiving subsidised food/fluid thickener via Special Authority for use in the community continue to receive subsidised food/fluid thickener should they wish to continue using it.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwO2AS'}, 'Id': 'a0POZ000004AlwO2AS', 'Event_Date__c': '2014-05-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 May 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'PTAC accepted the Subcommittee recommendations on thickeners. PTAC recommended that patients who are currently receiving subsidised food/fluid thickener via Special Authority for use in the community continue to receive subsidised food/fluid thickener should they wish to continue using it.', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqgeQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2017-12-v2.pdf"" target=""_blank"">Special Foods Subcommittee minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2017-12-v2.pdf"" target=""_blank"">Special Foods Subcommittee minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2017', 'fs': 'Dec 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Special Foods Subcommittee at meeting Thursday 7 December 2017.', 'fs': 'Clinical advice received from Special Foods Subcommittee at meeting Thursday 7 December 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwR2AS'}, 'Id': 'a0POZ000004AlwR2AS', 'Event_Date__c': '2017-12-07', 'Event_Description__c': 'Clinical advice received from Special Foods Subcommittee at meeting Thursday 7 December 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2017-12-v2.pdf"" target=""_blank"">Special Foods Subcommittee minutes</a></p>', 'Outcome__c': 'Recommended alteration to access criteria', 'Formatted_Date__c': 'Dec 2017', 'Status_History__c': 'a132P000000ArOFQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwS2AS'}, 'Id': 'a0POZ000004AlwS2AS', 'Event_Date__c': '2021-03-16', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CgrSQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Committee reaffirmed its previous recommendation that the community funding of food thickeners be delisted.</p><p><br></p><p>In reiterating its previous recommendation, the Committee noted that: </p><p><br></p><ul><li>people with dysphagia i.e. swallowing difficulties, have a high unmet health need, however, there was insufficient evidence that food thickeners would be expected to address these unmet needs and provide clinically meaningful benefits for people with dysphagia</li><li>there is some evidence of a risk of harm from use of food thickeners in dysphagia, namely reduced fluid intake, undernutrition, and potential reduction in quality of life</li><li>there are large numbers of patients with dysphagia from a range of causes, making it difficult to define a specific patient population that may benefit from food thickeners noting this would likely represent a substantial cost to the Combined Pharmaceutical Budget.</li></ul><p>The Committee acknowledged that there are inequities in the access to food thickeners in the community that may persist, be changed by, or be exacerbated if Pharmac were to delist food thickeners. However, the Committee considered it was not reasonable to recommend Pharmac continue to fund a treatment for which there is evidence that it can cause harm and poor evidence to support potential health benefits.\xa0</p><p><br></p>', 'fs': '<p>The Committee reaffirmed its previous recommendation that the community funding of food thickeners be delisted.</p><p><br></p><p>In reiterating its previous recommendation, the Committee noted that: </p><p><br></p><ul><li>people with dysphagia i.e. swallowing difficulties, have a high unmet health need, however, there was insufficient evidence that food thickeners would be expected to address these unmet needs and provide clinically meaningful benefits for people with dysphagia</li><li>there is some evidence of a risk of harm from use of food thickeners in dysphagia, namely reduced fluid intake, undernutrition, and potential reduction in quality of life</li><li>there are large numbers of patients with dysphagia from a range of causes, making it difficult to define a specific patient population that may benefit from food thickeners noting this would likely represent a substantial cost to the Combined Pharmaceutical Budget.</li></ul><p>The Committee acknowledged that there are inequities in the access to food thickeners in the community that may persist, be changed by, or be exacerbated if Pharmac were to delist food thickeners. However, the Committee considered it was not reasonable to recommend Pharmac continue to fund a treatment for which there is evidence that it can cause harm and poor evidence to support potential health benefits.\xa0</p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Committee noted that Pharmac sought advice regarding the evidence for use of food thickeners for dysphagia in the community. The Committee noted that Pharmac did not seek advice at this time regarding:</p><p><br></p><ul><li>consideration to widening the range of funded food thickeners, i.e. Pharmac is not seeking an evaluation of the products available</li><li>use of food thickeners in hospital</li><li>pre-thickened food or fluids</li><li>consideration to making any changes to the funding of food thickeners in hospital (through Section H of the Pharmaceutical Schedule).</li></ul><p><br></p><p>The Committee noted that food thickeners are funded for use in hospital and in the community for patients with dysphagia (swallowing difficulties), with community funding restricted to people with motor neurone disease with a swallowing disorder. The Committee noted that this restricted community funding was inconsistent with clinical practice, as dysphagia can occur in conditions other than motor neurone disease.</p><p><br></p><p>The Committee noted the extensive history of clinical advice from PTAC and PTAC Subcommittees for the use of food thickeners in the community. The Committee noted that the Special Foods Subcommittee of PTAC considered the following issues in 2001, which the Committee considered remained relevant:</p><p><br></p><ul><li>A substantial number of patients (potentially tens of thousands) may seek access to food thickeners, if funded; and</li><li>If funded, there would be increased use in private hospitals and rest homes due to cost-effectiveness of obtaining a product on prescription; and</li><li>There is a risk that food thickeners may be used before other alternatives have been trialled; and</li><li>The cost of food thickener would not be prohibitively high for most individuals.</li></ul><p><br></p><p>The Committee noted that the Special Foods Subcommittee of PTAC had further considered the use of food thickeners in dysphagia in 2013 and considered that there was no evidence to suggest any specific group of patients with dysphagia would receive greater benefits from food thickeners than any other group, and noted that the Subcommittee had made a recommendation to delist food thickeners from Section D of the Pharmaceutical Schedule based on weak and low-quality evidence.</p><p><br></p><p>The Committee noted that the New Zealand Formulary indicates use of thickeners either for infants under one year of age with significant gastro-oesophageal reflux, or for children over one year of age with dysphagia, but that the currently funded indication is only for motor neurone disease with a swallowing disorder.</p><p><br></p><p><i>Dysphagia</i></p><p><br></p><p>The Committee noted dysphagia is a medical term used to describe the symptom of difficulty swallowing food or liquid. The Committee noted dysphagia can be caused by or associated with a range of different diseases and pathological causes among different age groups, and considered that individuals may require different treatment approaches depending on the underlying cause.\xa0</p><p><br></p><p>The Committee noted that dysphagia affects the safety and efficacy of swallowing and may increase the risk of aspiration (where swallowed material enters the airways), aspiration pneumonia (a complication of aspiration into the lungs) and mortality. However, the Committee noted that not all aspiration pneumonia is caused by dysphagia. The Committee noted that other undesirable outcomes for dysphagia include reduced oral intake leading to malnutrition and dehydration, reduced quality of life, and increased risk of hospitalisation. </p><p><br></p><p>The Committee noted that dysphagia is relatively common, affecting about 13% of people in the community, about a quarter of people in hospitals, and about 60% of residents in aged care facilities. The Committee considered that the risk of dysphagia becomes more common across a person’s lifetime, although it can affect infants and children as well as adults. The Committee noted that most prevalence studies of dysphagia are in older adults, a group with a range of comorbidities. The Committee considered there was a large population with dysphagia from a variety of causes who may seek access to food thickeners and that it was difficult to define those with the greatest need. The Committee noted that Pharmac estimated 50% of people with dysphagia in the community may seek funded access to food thickeners for dysphagia, which could result in uptake by at least 27,000 people and potentially up to 65,000 people in the community over five years; the Committee considered these estimates were reasonable given the challenges in defining this broad and varied population.</p><p><br></p><p>The Committee noted that diagnosis and assessment of dysphagia may depend on an individual’s life stage and type of underlying disease but noted that patients may be assessed in hospital or community settings. The Committee noted that about 10% of patients diagnosed with dysphagia in hospital are prescribed food thickeners on discharge. The Committee noted that patients diagnosed with dysphagia in the community include adults in residential aged care facilities affected by oncologic and neurological causes of dysphagia, and babies with persistent gastro-oesophageal reflux disease (GORD).</p><p><br></p><p>The Committee noted that, depending on disease pathology, patients with dysphagia may be referred for a clinical assessment of swallowing by a Speech Language Therapist (SLT) including a videofluoroscopic swallowing study (VFSS) as noted in New Zealand Speech-language Therapy Clinical Practice Guideline on Videofluoroscopic Swallowing Study (VFSS; Revised March 2020) and/or a bedside swallow assessment. The Committee noted that VFSS is performed in radiology departments and therefore would compete with other radiology priorities for resources. Members considered that, while VFSS is considered a gold standard for diagnosis of aspiration, it was unclear whether this would accurately predict the risk of aspiration pneumonia.</p><p><br></p><p>The Committee noted that there are a limited number of Speech Language Therapist in the country and that timely access to Speech Language Therapists can be difficult.</p><p><br></p><p><i>Food thickeners</i></p><p><br></p><p>The Committee noted that benefits associated with food thickeners for dysphagia are theoretically plausible given the mechanics of swallowing noting that thickening fluids is intended to reduce the speed of bolus flow during swallowing, which is considered useful to reduce the risk of laryngeal penetration and aspiration. The Committee was made aware of a systematic review of short-duration studies which investigated the prevalence of penetration and aspiration according to liquid thickness, and which reported lower prevalence of aspiration with thicker liquids (Newman et al. Dysphagia. 2016;31:232-49). The Committee considered it theoretically plausible that a reduction in the risk of aspiration could as a consequence reduce the risk of aspiration pneumonia.</p><p><br></p><p>The Committee noted Pharmac’s request for information regarding food thickeners in January 2021 and that more than a quarter of respondents were Speech-Language Therapists. The Committee noted that responses indicated there is broad use of food thickeners across many diseases and age groups, as recommended by various professional groups.\xa0</p><p><br></p><p>The Committee noted that thicknesses of foods and liquids are standardised in the IDDSI framework (The International Dysphagia Diet Standardisation Initiative 2019). The Committee was made aware of international guidelines regarding considerations for use of food thickener in individual patients which were based on clinical opinion and required swallowing assessment (McCurtin et al. J Eval Clin Pract. 2020;26:1744-60).</p><p><br></p><p>The Committee noted that there was no new primary research or clinical trial evidence for food thickeners in dysphagia, including dysphagia in motor neurone disease, and that newly published systematic reviews included previously reviewed primary evidence. The Committee considered that there was no new evidence to support the perceived benefits from food thickeners, and that these perceived benefits remained informed by evidence of short-term response and clinical evaluation (either VFSS or bedside).</p><p><br></p><p>The Committee noted the following recent evidence for effectiveness of food thickeners in dysphagia from three systematic reviews (none of which included new primary evidence):</p><p><br></p><p class=""ql-indent-1"">A systematic review of texture-modified foods and liquids for patients aged 18 years and over with oropharyngeal dysphagia in acute or chronic care who were known to aspirate as demonstrated by VFSS (Beck et al. Clin Nutr. 2018;37:1980- 91). The authors investigated outcomes including pneumonia and death, aspiration, dehydration, nutritional status, patient preferences and quality of life (among others) and included randomised controlled trials, guidelines, systematic reviews including Cochrane reviews and qualitative studies in this review. </p><p><br></p><p class=""ql-indent-2"">The Committee noted that no studies were identified for texture-modified foods. The Committee noted that only two studies of texture-modified liquids (nectar or honey thickened liquids) were identified and that these were randomised controlled trials published in 2008 which included patients with Parkinson disease and/or dementia. The Committee noted aspiration was confirmed by VFSS; the comparator was a thin liquid, and the interventions used a ‘chin-down’ posture. </p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that one study reported the three-month cumulative incidence of pneumonia was 0.098 in the chin-down posture group and 0.116 in the thickened liquid group (0.084 nectar-thick and 0.150 honey-thick). The Committee noted that the highest cumulative incidence of pneumonia was with honey-thickened fluids. </p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the other study reported VFSS-identified aspiration was 68% with thin liquid, 53% with honey consistency (P&lt;0.0001) and 63% with nectar consistency (P&lt;0.001).</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the authors of the systematic review reported trends towards a reduction in exacerbations and a reduction in pneumonia, although each was informed by low quality evidence. The Committee also noted a trend towards increased weight loss and dehydration with modified textures compared with normal diet/usual care, and considered this was evidence of potential harm from thickened fluids.</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the systematic review was used to update the Danish 2012 national clinical guideline on use of textured modified foods and thickened liquids in adults with dysphagia. The updated recommendation was that “based on the quality of the evidence, assessment of the risk benefit ratio, and perceived patient preferences a weak recommendation against the use of texture modified liquids” is made. </p><p class=""ql-indent-2""><br></p><p>A Cochrane systematic review of modifying the consistency of food and fluids for swallowing difficulties in dementia (Flynn et al. Cochrane Database Syst Rev. 2018;9:CD011077), was based on the same two clinical trials as the Beck et al. systematic review and therefore provided no additional evidence.</p><p class=""ql-indent-2""><br></p><p>An updated Cochrane systematic review of formula-fed healthy term infants up to six months of age with gastro-oesophageal reflux who received food thickener or control (Kwok et al. Cochrane Database Syst Rev. 2017 Dec 5;12(12):CD003211). The Committee considered that this patient group with dysphagia would commonly be seen in primary care in GP clinics, for episodic management, although gastro-oesophageal reflux may be self-resolving and may not require treatment.</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-1"">The Committee noted that eight trials recruiting a total of 637 infants met the inclusion criteria for the systematic review. The Committee noted there was moderate quality evidence of a reduction in the number of episodes of regurgitation per day with feed thickeners and that the authors reported a reduction of two episodes of regurgitation per day may be clinically significant to caregivers. The Committee considered this evidence showed a potential for use of food thickeners in infants and reflected clinical practice; however acknowledged that regurgitation was a self-resolving phenomenon in this population.</p><p class=""ql-indent-2""><br></p><p>The Committee also noted the following evidence:</p><p class=""ql-indent-2""><br></p><ul><li>O’Keeffe et al. BMC Geriatr. 2018;18:167</li><li>Lippert et al. J Hosp Med. 2019;14:315-7</li><li>Wallis et al. Pediatr Allergy Immunol Pulmonol. 2012;25:132-42</li><li>Duncan et al. Curr Gastroenterol Rep. 2019;21:30</li><li>Leder et al. Dysphagia. 2013;28:58-62</li><li>Das et al. UpToDate. 2020. Accessed 22 April 2021.</li><li>Duncan et al. Curr Gastroenterol Rep. 2019;21:30</li><li>Ramakrishnam et al. Curr Gastroenterol Rep. 2002;4:218-24.</li><li>Duncan et al. J Pediatr Gastroenterol Nutr. 2019;68:218-24.</li><li>Gurberg et al. Int J Pediatr Otorhinolaryngol. 2015;79:1827-30</li><li>Piccione et al. Pediatr Pulmonl. 2012;47:447-52</li><li>Steele et al. Dysphagia. 2015;30:2-2</li><li>Diniz et al. Nutr Clin Pract. 2009;24:414-8</li><li>Robbins et al. Ann Intern Med. 2008;148:509-18</li><li>Ozaki et al. Tohoku J Exp Med. 2010;220:41-6</li><li>Foley et al. Age Ageing. 2008;37:258-64</li><li>Campbell-Taylor, I. J Am Med Dir Assoc. 2008;9:523-31</li><li>Coyle et al. J Am Med Dir Assoc. 2009;10:62-6; discussion 79-83</li><li>Horvath et al. Pediatrics. 2008;122:e1268-77</li><li>Huang et al. Cochrane Database Syst Rev. 2002;(3):CD003211</li><li>Garcia et al. Nutr Hosp. 2015;31 Suppl 5:56-66</li><li>Jesus et al. Amyotroph Lateral Scler. 2012;13:538-43</li><li>Pezzana et al. J Nutr Health Aging. 2015;19:947-54</li><li>Rofes et al. Gut. 2013;62:1280-7</li><li>Wright et al. Geriatrics (Basel). 2020;5:9</li><li>Sukkar et al. Front Nutr. 2018 7;5:68</li><li>Hwang et al. Ann Rehabil Med. 2017;41:9-15</li><li>Trelis et al. Nutr Hosp. 2002;17:168-74</li><li> Vilardell et al. Dysphagia. 2016;31:169-79</li><li>Sezgin et al. Eur Arch Otorhinolaryngol. 2018;275:2997-3005</li><li>Miranda et al. Nutr Clin Pract. 2020;35:649-54</li><li>Tomita et al. Dysphagia. 2017;32:449-53</li><li>Tomita et al. Yakugaku Zasshi. 2016;136:1171-6</li></ul><p class=""ql-indent-2""><br></p><p>The Committee considered that the evidence for food thickeners does not support wider use in practice, that there is a lack of good quality evidence that thickening liquids reduces pneumonia in dysphagia, and that there is some risk that food thickeners may be associated with reduced fluid intake, undernutrition and potential reduction in quality of life. The Committee considered that the use of food thickeners in practice was often based on expert clinical opinion, in the absence of good quality evidence that all patients with dysphagia would benefit from food thickeners.</p><p><br></p><p>Members considered that thickened fluids may not be in the best interest of all patients in some cases other forms of supportive palliative care for symptom management may be more appropriate. Members also considered that thickened fluids can increase the risk of pneumonia in patients with vocal cord dysfunction who cannot effectively protect their airway and may aspirate thickened fluids. Members considered that patients with severe dysphagia remained at risk of silently aspirating at times when not consuming food and fluids, regardless of the use of thickened products.</p><p><br></p><p>Overall, the Committee considered that the evidence base for food thickeners in dysphagia included poor quality evidence with differing assessments of this evidence by different professional groups (Campbell-Taylor I. 2008; Coyle et al. 2009; O’Keeffe et al. 2018; Lippert et al. 2019). Members considered that reasonable quality evidence could be expected in this setting, given the high prevalence of dysphagia across age groups and disease types.</p><p><br></p><p><i>General</i> </p><p><br></p><p>The Committee acknowledged the clinical input provided in response to Pharmac’s request for information and recognised the feedback regarding the inconsistency in access to food thickeners in the community and equity concerns associated with this. The Committee noted that there were likely further inequities due to regional variation in access to Speech-Language Therapists.</p><p><br></p><p>The Committee considered that there was a large potential clinical group with health need due to dysphagia but that this group was hard to define, and additionally that it was not possible to identify a population with the greatest need who could be targeted by funded treatment. The Committee considered that this presented significant fiscal risk with little to no evidence of clinical benefit and evidence of potential net harm.</p><p><br></p><p>The Committee acknowledged the high health need of people with dysphagia but noted that there is no evidence that food thickeners would address the unmet need of patients with dysphagia and some evidence that food thickeners may worsen health outcomes and lead to harm. The Committee reiterated its previous recommendation and support to delist food thickeners from the community funding schedule.\xa0\xa0</p><p><br></p><p>\xa0</p>', 'fs': '<p>The Committee noted that Pharmac sought advice regarding the evidence for use of food thickeners for dysphagia in the community. The Committee noted that Pharmac did not seek advice at this time regarding:</p><p><br></p><ul><li>consideration to widening the range of funded food thickeners, i.e. Pharmac is not seeking an evaluation of the products available</li><li>use of food thickeners in hospital</li><li>pre-thickened food or fluids</li><li>consideration to making any changes to the funding of food thickeners in hospital (through Section H of the Pharmaceutical Schedule).</li></ul><p><br></p><p>The Committee noted that food thickeners are funded for use in hospital and in the community for patients with dysphagia (swallowing difficulties), with community funding restricted to people with motor neurone disease with a swallowing disorder. The Committee noted that this restricted community funding was inconsistent with clinical practice, as dysphagia can occur in conditions other than motor neurone disease.</p><p><br></p><p>The Committee noted the extensive history of clinical advice from PTAC and PTAC Subcommittees for the use of food thickeners in the community. The Committee noted that the Special Foods Subcommittee of PTAC considered the following issues in 2001, which the Committee considered remained relevant:</p><p><br></p><ul><li>A substantial number of patients (potentially tens of thousands) may seek access to food thickeners, if funded; and</li><li>If funded, there would be increased use in private hospitals and rest homes due to cost-effectiveness of obtaining a product on prescription; and</li><li>There is a risk that food thickeners may be used before other alternatives have been trialled; and</li><li>The cost of food thickener would not be prohibitively high for most individuals.</li></ul><p><br></p><p>The Committee noted that the Special Foods Subcommittee of PTAC had further considered the use of food thickeners in dysphagia in 2013 and considered that there was no evidence to suggest any specific group of patients with dysphagia would receive greater benefits from food thickeners than any other group, and noted that the Subcommittee had made a recommendation to delist food thickeners from Section D of the Pharmaceutical Schedule based on weak and low-quality evidence.</p><p><br></p><p>The Committee noted that the New Zealand Formulary indicates use of thickeners either for infants under one year of age with significant gastro-oesophageal reflux, or for children over one year of age with dysphagia, but that the currently funded indication is only for motor neurone disease with a swallowing disorder.</p><p><br></p><p><i>Dysphagia</i></p><p><br></p><p>The Committee noted dysphagia is a medical term used to describe the symptom of difficulty swallowing food or liquid. The Committee noted dysphagia can be caused by or associated with a range of different diseases and pathological causes among different age groups, and considered that individuals may require different treatment approaches depending on the underlying cause.\xa0</p><p><br></p><p>The Committee noted that dysphagia affects the safety and efficacy of swallowing and may increase the risk of aspiration (where swallowed material enters the airways), aspiration pneumonia (a complication of aspiration into the lungs) and mortality. However, the Committee noted that not all aspiration pneumonia is caused by dysphagia. The Committee noted that other undesirable outcomes for dysphagia include reduced oral intake leading to malnutrition and dehydration, reduced quality of life, and increased risk of hospitalisation. </p><p><br></p><p>The Committee noted that dysphagia is relatively common, affecting about 13% of people in the community, about a quarter of people in hospitals, and about 60% of residents in aged care facilities. The Committee considered that the risk of dysphagia becomes more common across a person’s lifetime, although it can affect infants and children as well as adults. The Committee noted that most prevalence studies of dysphagia are in older adults, a group with a range of comorbidities. The Committee considered there was a large population with dysphagia from a variety of causes who may seek access to food thickeners and that it was difficult to define those with the greatest need. The Committee noted that Pharmac estimated 50% of people with dysphagia in the community may seek funded access to food thickeners for dysphagia, which could result in uptake by at least 27,000 people and potentially up to 65,000 people in the community over five years; the Committee considered these estimates were reasonable given the challenges in defining this broad and varied population.</p><p><br></p><p>The Committee noted that diagnosis and assessment of dysphagia may depend on an individual’s life stage and type of underlying disease but noted that patients may be assessed in hospital or community settings. The Committee noted that about 10% of patients diagnosed with dysphagia in hospital are prescribed food thickeners on discharge. The Committee noted that patients diagnosed with dysphagia in the community include adults in residential aged care facilities affected by oncologic and neurological causes of dysphagia, and babies with persistent gastro-oesophageal reflux disease (GORD).</p><p><br></p><p>The Committee noted that, depending on disease pathology, patients with dysphagia may be referred for a clinical assessment of swallowing by a Speech Language Therapist (SLT) including a videofluoroscopic swallowing study (VFSS) as noted in New Zealand Speech-language Therapy Clinical Practice Guideline on Videofluoroscopic Swallowing Study (VFSS; Revised March 2020) and/or a bedside swallow assessment. The Committee noted that VFSS is performed in radiology departments and therefore would compete with other radiology priorities for resources. Members considered that, while VFSS is considered a gold standard for diagnosis of aspiration, it was unclear whether this would accurately predict the risk of aspiration pneumonia.</p><p><br></p><p>The Committee noted that there are a limited number of Speech Language Therapist in the country and that timely access to Speech Language Therapists can be difficult.</p><p><br></p><p><i>Food thickeners</i></p><p><br></p><p>The Committee noted that benefits associated with food thickeners for dysphagia are theoretically plausible given the mechanics of swallowing noting that thickening fluids is intended to reduce the speed of bolus flow during swallowing, which is considered useful to reduce the risk of laryngeal penetration and aspiration. The Committee was made aware of a systematic review of short-duration studies which investigated the prevalence of penetration and aspiration according to liquid thickness, and which reported lower prevalence of aspiration with thicker liquids (Newman et al. Dysphagia. 2016;31:232-49). The Committee considered it theoretically plausible that a reduction in the risk of aspiration could as a consequence reduce the risk of aspiration pneumonia.</p><p><br></p><p>The Committee noted Pharmac’s request for information regarding food thickeners in January 2021 and that more than a quarter of respondents were Speech-Language Therapists. The Committee noted that responses indicated there is broad use of food thickeners across many diseases and age groups, as recommended by various professional groups.\xa0</p><p><br></p><p>The Committee noted that thicknesses of foods and liquids are standardised in the IDDSI framework (The International Dysphagia Diet Standardisation Initiative 2019). The Committee was made aware of international guidelines regarding considerations for use of food thickener in individual patients which were based on clinical opinion and required swallowing assessment (McCurtin et al. J Eval Clin Pract. 2020;26:1744-60).</p><p><br></p><p>The Committee noted that there was no new primary research or clinical trial evidence for food thickeners in dysphagia, including dysphagia in motor neurone disease, and that newly published systematic reviews included previously reviewed primary evidence. The Committee considered that there was no new evidence to support the perceived benefits from food thickeners, and that these perceived benefits remained informed by evidence of short-term response and clinical evaluation (either VFSS or bedside).</p><p><br></p><p>The Committee noted the following recent evidence for effectiveness of food thickeners in dysphagia from three systematic reviews (none of which included new primary evidence):</p><p><br></p><p class=""ql-indent-1"">A systematic review of texture-modified foods and liquids for patients aged 18 years and over with oropharyngeal dysphagia in acute or chronic care who were known to aspirate as demonstrated by VFSS (Beck et al. Clin Nutr. 2018;37:1980- 91). The authors investigated outcomes including pneumonia and death, aspiration, dehydration, nutritional status, patient preferences and quality of life (among others) and included randomised controlled trials, guidelines, systematic reviews including Cochrane reviews and qualitative studies in this review. </p><p><br></p><p class=""ql-indent-2"">The Committee noted that no studies were identified for texture-modified foods. The Committee noted that only two studies of texture-modified liquids (nectar or honey thickened liquids) were identified and that these were randomised controlled trials published in 2008 which included patients with Parkinson disease and/or dementia. The Committee noted aspiration was confirmed by VFSS; the comparator was a thin liquid, and the interventions used a ‘chin-down’ posture. </p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that one study reported the three-month cumulative incidence of pneumonia was 0.098 in the chin-down posture group and 0.116 in the thickened liquid group (0.084 nectar-thick and 0.150 honey-thick). The Committee noted that the highest cumulative incidence of pneumonia was with honey-thickened fluids. </p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the other study reported VFSS-identified aspiration was 68% with thin liquid, 53% with honey consistency (P&lt;0.0001) and 63% with nectar consistency (P&lt;0.001).</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the authors of the systematic review reported trends towards a reduction in exacerbations and a reduction in pneumonia, although each was informed by low quality evidence. The Committee also noted a trend towards increased weight loss and dehydration with modified textures compared with normal diet/usual care, and considered this was evidence of potential harm from thickened fluids.</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the systematic review was used to update the Danish 2012 national clinical guideline on use of textured modified foods and thickened liquids in adults with dysphagia. The updated recommendation was that “based on the quality of the evidence, assessment of the risk benefit ratio, and perceived patient preferences a weak recommendation against the use of texture modified liquids” is made. </p><p class=""ql-indent-2""><br></p><p>A Cochrane systematic review of modifying the consistency of food and fluids for swallowing difficulties in dementia (Flynn et al. Cochrane Database Syst Rev. 2018;9:CD011077), was based on the same two clinical trials as the Beck et al. systematic review and therefore provided no additional evidence.</p><p class=""ql-indent-2""><br></p><p>An updated Cochrane systematic review of formula-fed healthy term infants up to six months of age with gastro-oesophageal reflux who received food thickener or control (Kwok et al. Cochrane Database Syst Rev. 2017 Dec 5;12(12):CD003211). The Committee considered that this patient group with dysphagia would commonly be seen in primary care in GP clinics, for episodic management, although gastro-oesophageal reflux may be self-resolving and may not require treatment.</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-1"">The Committee noted that eight trials recruiting a total of 637 infants met the inclusion criteria for the systematic review. The Committee noted there was moderate quality evidence of a reduction in the number of episodes of regurgitation per day with feed thickeners and that the authors reported a reduction of two episodes of regurgitation per day may be clinically significant to caregivers. The Committee considered this evidence showed a potential for use of food thickeners in infants and reflected clinical practice; however acknowledged that regurgitation was a self-resolving phenomenon in this population.</p><p class=""ql-indent-2""><br></p><p>The Committee also noted the following evidence:</p><p class=""ql-indent-2""><br></p><ul><li>O’Keeffe et al. BMC Geriatr. 2018;18:167</li><li>Lippert et al. J Hosp Med. 2019;14:315-7</li><li>Wallis et al. Pediatr Allergy Immunol Pulmonol. 2012;25:132-42</li><li>Duncan et al. Curr Gastroenterol Rep. 2019;21:30</li><li>Leder et al. Dysphagia. 2013;28:58-62</li><li>Das et al. UpToDate. 2020. Accessed 22 April 2021.</li><li>Duncan et al. Curr Gastroenterol Rep. 2019;21:30</li><li>Ramakrishnam et al. Curr Gastroenterol Rep. 2002;4:218-24.</li><li>Duncan et al. J Pediatr Gastroenterol Nutr. 2019;68:218-24.</li><li>Gurberg et al. Int J Pediatr Otorhinolaryngol. 2015;79:1827-30</li><li>Piccione et al. Pediatr Pulmonl. 2012;47:447-52</li><li>Steele et al. Dysphagia. 2015;30:2-2</li><li>Diniz et al. Nutr Clin Pract. 2009;24:414-8</li><li>Robbins et al. Ann Intern Med. 2008;148:509-18</li><li>Ozaki et al. Tohoku J Exp Med. 2010;220:41-6</li><li>Foley et al. Age Ageing. 2008;37:258-64</li><li>Campbell-Taylor, I. J Am Med Dir Assoc. 2008;9:523-31</li><li>Coyle et al. J Am Med Dir Assoc. 2009;10:62-6; discussion 79-83</li><li>Horvath et al. Pediatrics. 2008;122:e1268-77</li><li>Huang et al. Cochrane Database Syst Rev. 2002;(3):CD003211</li><li>Garcia et al. Nutr Hosp. 2015;31 Suppl 5:56-66</li><li>Jesus et al. Amyotroph Lateral Scler. 2012;13:538-43</li><li>Pezzana et al. J Nutr Health Aging. 2015;19:947-54</li><li>Rofes et al. Gut. 2013;62:1280-7</li><li>Wright et al. Geriatrics (Basel). 2020;5:9</li><li>Sukkar et al. Front Nutr. 2018 7;5:68</li><li>Hwang et al. Ann Rehabil Med. 2017;41:9-15</li><li>Trelis et al. Nutr Hosp. 2002;17:168-74</li><li> Vilardell et al. Dysphagia. 2016;31:169-79</li><li>Sezgin et al. Eur Arch Otorhinolaryngol. 2018;275:2997-3005</li><li>Miranda et al. Nutr Clin Pract. 2020;35:649-54</li><li>Tomita et al. Dysphagia. 2017;32:449-53</li><li>Tomita et al. Yakugaku Zasshi. 2016;136:1171-6</li></ul><p class=""ql-indent-2""><br></p><p>The Committee considered that the evidence for food thickeners does not support wider use in practice, that there is a lack of good quality evidence that thickening liquids reduces pneumonia in dysphagia, and that there is some risk that food thickeners may be associated with reduced fluid intake, undernutrition and potential reduction in quality of life. The Committee considered that the use of food thickeners in practice was often based on expert clinical opinion, in the absence of good quality evidence that all patients with dysphagia would benefit from food thickeners.</p><p><br></p><p>Members considered that thickened fluids may not be in the best interest of all patients in some cases other forms of supportive palliative care for symptom management may be more appropriate. Members also considered that thickened fluids can increase the risk of pneumonia in patients with vocal cord dysfunction who cannot effectively protect their airway and may aspirate thickened fluids. Members considered that patients with severe dysphagia remained at risk of silently aspirating at times when not consuming food and fluids, regardless of the use of thickened products.</p><p><br></p><p>Overall, the Committee considered that the evidence base for food thickeners in dysphagia included poor quality evidence with differing assessments of this evidence by different professional groups (Campbell-Taylor I. 2008; Coyle et al. 2009; O’Keeffe et al. 2018; Lippert et al. 2019). Members considered that reasonable quality evidence could be expected in this setting, given the high prevalence of dysphagia across age groups and disease types.</p><p><br></p><p><i>General</i> </p><p><br></p><p>The Committee acknowledged the clinical input provided in response to Pharmac’s request for information and recognised the feedback regarding the inconsistency in access to food thickeners in the community and equity concerns associated with this. The Committee noted that there were likely further inequities due to regional variation in access to Speech-Language Therapists.</p><p><br></p><p>The Committee considered that there was a large potential clinical group with health need due to dysphagia but that this group was hard to define, and additionally that it was not possible to identify a population with the greatest need who could be targeted by funded treatment. The Committee considered that this presented significant fiscal risk with little to no evidence of clinical benefit and evidence of potential net harm.</p><p><br></p><p>The Committee acknowledged the high health need of people with dysphagia but noted that there is no evidence that food thickeners would address the unmet need of patients with dysphagia and some evidence that food thickeners may worsen health outcomes and lead to harm. The Committee reiterated its previous recommendation and support to delist food thickeners from the community funding schedule.\xa0\xa0</p><p><br></p><p>\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>The Committee considered the funding of food thickeners in the community for the management of dysphagia, following receipt of evidence and information that was provided in response to Pharmac’s request for information released in January 2021.</p>', 'fs': '<p>The Committee considered the funding of food thickeners in the community for the management of dysphagia, following receipt of evidence and information that was provided in response to Pharmac’s request for information released in January 2021.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">PTAC minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">PTAC minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 21 May 2021.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 21 May 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwT2AS'}, 'Id': 'a0POZ000004AlwT2AS', 'Event_Date__c': '2021-08-06', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 21 May 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">PTAC minutes</a></p>', 'Formatted_Date__c': 'Aug 2021', 'Published_Recommendation__c': '<p>The Committee reaffirmed its previous recommendation that the community funding of food thickeners be delisted.</p><p><br></p><p>In reiterating its previous recommendation, the Committee noted that: </p><p><br></p><ul><li>people with dysphagia i.e. swallowing difficulties, have a high unmet health need, however, there was insufficient evidence that food thickeners would be expected to address these unmet needs and provide clinically meaningful benefits for people with dysphagia</li><li>there is some evidence of a risk of harm from use of food thickeners in dysphagia, namely reduced fluid intake, undernutrition, and potential reduction in quality of life</li><li>there are large numbers of patients with dysphagia from a range of causes, making it difficult to define a specific patient population that may benefit from food thickeners noting this would likely represent a substantial cost to the Combined Pharmaceutical Budget.</li></ul><p>The Committee acknowledged that there are inequities in the access to food thickeners in the community that may persist, be changed by, or be exacerbated if Pharmac were to delist food thickeners. However, the Committee considered it was not reasonable to recommend Pharmac continue to fund a treatment for which there is evidence that it can cause harm and poor evidence to support potential health benefits.\xa0</p><p><br></p>', 'Published_Application__c': '<p>The Committee considered the funding of food thickeners in the community for the management of dysphagia, following receipt of evidence and information that was provided in response to Pharmac’s request for information released in January 2021.</p>', 'Published_Discussion__c': '<p>The Committee noted that Pharmac sought advice regarding the evidence for use of food thickeners for dysphagia in the community. The Committee noted that Pharmac did not seek advice at this time regarding:</p><p><br></p><ul><li>consideration to widening the range of funded food thickeners, i.e. Pharmac is not seeking an evaluation of the products available</li><li>use of food thickeners in hospital</li><li>pre-thickened food or fluids</li><li>consideration to making any changes to the funding of food thickeners in hospital (through Section H of the Pharmaceutical Schedule).</li></ul><p><br></p><p>The Committee noted that food thickeners are funded for use in hospital and in the community for patients with dysphagia (swallowing difficulties), with community funding restricted to people with motor neurone disease with a swallowing disorder. The Committee noted that this restricted community funding was inconsistent with clinical practice, as dysphagia can occur in conditions other than motor neurone disease.</p><p><br></p><p>The Committee noted the extensive history of clinical advice from PTAC and PTAC Subcommittees for the use of food thickeners in the community. The Committee noted that the Special Foods Subcommittee of PTAC considered the following issues in 2001, which the Committee considered remained relevant:</p><p><br></p><ul><li>A substantial number of patients (potentially tens of thousands) may seek access to food thickeners, if funded; and</li><li>If funded, there would be increased use in private hospitals and rest homes due to cost-effectiveness of obtaining a product on prescription; and</li><li>There is a risk that food thickeners may be used before other alternatives have been trialled; and</li><li>The cost of food thickener would not be prohibitively high for most individuals.</li></ul><p><br></p><p>The Committee noted that the Special Foods Subcommittee of PTAC had further considered the use of food thickeners in dysphagia in 2013 and considered that there was no evidence to suggest any specific group of patients with dysphagia would receive greater benefits from food thickeners than any other group, and noted that the Subcommittee had made a recommendation to delist food thickeners from Section D of the Pharmaceutical Schedule based on weak and low-quality evidence.</p><p><br></p><p>The Committee noted that the New Zealand Formulary indicates use of thickeners either for infants under one year of age with significant gastro-oesophageal reflux, or for children over one year of age with dysphagia, but that the currently funded indication is only for motor neurone disease with a swallowing disorder.</p><p><br></p><p><i>Dysphagia</i></p><p><br></p><p>The Committee noted dysphagia is a medical term used to describe the symptom of difficulty swallowing food or liquid. The Committee noted dysphagia can be caused by or associated with a range of different diseases and pathological causes among different age groups, and considered that individuals may require different treatment approaches depending on the underlying cause.\xa0</p><p><br></p><p>The Committee noted that dysphagia affects the safety and efficacy of swallowing and may increase the risk of aspiration (where swallowed material enters the airways), aspiration pneumonia (a complication of aspiration into the lungs) and mortality. However, the Committee noted that not all aspiration pneumonia is caused by dysphagia. The Committee noted that other undesirable outcomes for dysphagia include reduced oral intake leading to malnutrition and dehydration, reduced quality of life, and increased risk of hospitalisation. </p><p><br></p><p>The Committee noted that dysphagia is relatively common, affecting about 13% of people in the community, about a quarter of people in hospitals, and about 60% of residents in aged care facilities. The Committee considered that the risk of dysphagia becomes more common across a person’s lifetime, although it can affect infants and children as well as adults. The Committee noted that most prevalence studies of dysphagia are in older adults, a group with a range of comorbidities. The Committee considered there was a large population with dysphagia from a variety of causes who may seek access to food thickeners and that it was difficult to define those with the greatest need. The Committee noted that Pharmac estimated 50% of people with dysphagia in the community may seek funded access to food thickeners for dysphagia, which could result in uptake by at least 27,000 people and potentially up to 65,000 people in the community over five years; the Committee considered these estimates were reasonable given the challenges in defining this broad and varied population.</p><p><br></p><p>The Committee noted that diagnosis and assessment of dysphagia may depend on an individual’s life stage and type of underlying disease but noted that patients may be assessed in hospital or community settings. The Committee noted that about 10% of patients diagnosed with dysphagia in hospital are prescribed food thickeners on discharge. The Committee noted that patients diagnosed with dysphagia in the community include adults in residential aged care facilities affected by oncologic and neurological causes of dysphagia, and babies with persistent gastro-oesophageal reflux disease (GORD).</p><p><br></p><p>The Committee noted that, depending on disease pathology, patients with dysphagia may be referred for a clinical assessment of swallowing by a Speech Language Therapist (SLT) including a videofluoroscopic swallowing study (VFSS) as noted in New Zealand Speech-language Therapy Clinical Practice Guideline on Videofluoroscopic Swallowing Study (VFSS; Revised March 2020) and/or a bedside swallow assessment. The Committee noted that VFSS is performed in radiology departments and therefore would compete with other radiology priorities for resources. Members considered that, while VFSS is considered a gold standard for diagnosis of aspiration, it was unclear whether this would accurately predict the risk of aspiration pneumonia.</p><p><br></p><p>The Committee noted that there are a limited number of Speech Language Therapist in the country and that timely access to Speech Language Therapists can be difficult.</p><p><br></p><p><i>Food thickeners</i></p><p><br></p><p>The Committee noted that benefits associated with food thickeners for dysphagia are theoretically plausible given the mechanics of swallowing noting that thickening fluids is intended to reduce the speed of bolus flow during swallowing, which is considered useful to reduce the risk of laryngeal penetration and aspiration. The Committee was made aware of a systematic review of short-duration studies which investigated the prevalence of penetration and aspiration according to liquid thickness, and which reported lower prevalence of aspiration with thicker liquids (Newman et al. Dysphagia. 2016;31:232-49). The Committee considered it theoretically plausible that a reduction in the risk of aspiration could as a consequence reduce the risk of aspiration pneumonia.</p><p><br></p><p>The Committee noted Pharmac’s request for information regarding food thickeners in January 2021 and that more than a quarter of respondents were Speech-Language Therapists. The Committee noted that responses indicated there is broad use of food thickeners across many diseases and age groups, as recommended by various professional groups.\xa0</p><p><br></p><p>The Committee noted that thicknesses of foods and liquids are standardised in the IDDSI framework (The International Dysphagia Diet Standardisation Initiative 2019). The Committee was made aware of international guidelines regarding considerations for use of food thickener in individual patients which were based on clinical opinion and required swallowing assessment (McCurtin et al. J Eval Clin Pract. 2020;26:1744-60).</p><p><br></p><p>The Committee noted that there was no new primary research or clinical trial evidence for food thickeners in dysphagia, including dysphagia in motor neurone disease, and that newly published systematic reviews included previously reviewed primary evidence. The Committee considered that there was no new evidence to support the perceived benefits from food thickeners, and that these perceived benefits remained informed by evidence of short-term response and clinical evaluation (either VFSS or bedside).</p><p><br></p><p>The Committee noted the following recent evidence for effectiveness of food thickeners in dysphagia from three systematic reviews (none of which included new primary evidence):</p><p><br></p><p class=""ql-indent-1"">A systematic review of texture-modified foods and liquids for patients aged 18 years and over with oropharyngeal dysphagia in acute or chronic care who were known to aspirate as demonstrated by VFSS (Beck et al. Clin Nutr. 2018;37:1980- 91). The authors investigated outcomes including pneumonia and death, aspiration, dehydration, nutritional status, patient preferences and quality of life (among others) and included randomised controlled trials, guidelines, systematic reviews including Cochrane reviews and qualitative studies in this review. </p><p><br></p><p class=""ql-indent-2"">The Committee noted that no studies were identified for texture-modified foods. The Committee noted that only two studies of texture-modified liquids (nectar or honey thickened liquids) were identified and that these were randomised controlled trials published in 2008 which included patients with Parkinson disease and/or dementia. The Committee noted aspiration was confirmed by VFSS; the comparator was a thin liquid, and the interventions used a ‘chin-down’ posture. </p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that one study reported the three-month cumulative incidence of pneumonia was 0.098 in the chin-down posture group and 0.116 in the thickened liquid group (0.084 nectar-thick and 0.150 honey-thick). The Committee noted that the highest cumulative incidence of pneumonia was with honey-thickened fluids. </p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the other study reported VFSS-identified aspiration was 68% with thin liquid, 53% with honey consistency (P&lt;0.0001) and 63% with nectar consistency (P&lt;0.001).</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the authors of the systematic review reported trends towards a reduction in exacerbations and a reduction in pneumonia, although each was informed by low quality evidence. The Committee also noted a trend towards increased weight loss and dehydration with modified textures compared with normal diet/usual care, and considered this was evidence of potential harm from thickened fluids.</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-2"">The Committee noted that the systematic review was used to update the Danish 2012 national clinical guideline on use of textured modified foods and thickened liquids in adults with dysphagia. The updated recommendation was that “based on the quality of the evidence, assessment of the risk benefit ratio, and perceived patient preferences a weak recommendation against the use of texture modified liquids” is made. </p><p class=""ql-indent-2""><br></p><p>A Cochrane systematic review of modifying the consistency of food and fluids for swallowing difficulties in dementia (Flynn et al. Cochrane Database Syst Rev. 2018;9:CD011077), was based on the same two clinical trials as the Beck et al. systematic review and therefore provided no additional evidence.</p><p class=""ql-indent-2""><br></p><p>An updated Cochrane systematic review of formula-fed healthy term infants up to six months of age with gastro-oesophageal reflux who received food thickener or control (Kwok et al. Cochrane Database Syst Rev. 2017 Dec 5;12(12):CD003211). The Committee considered that this patient group with dysphagia would commonly be seen in primary care in GP clinics, for episodic management, although gastro-oesophageal reflux may be self-resolving and may not require treatment.</p><p class=""ql-indent-2""><br></p><p class=""ql-indent-1"">The Committee noted that eight trials recruiting a total of 637 infants met the inclusion criteria for the systematic review. The Committee noted there was moderate quality evidence of a reduction in the number of episodes of regurgitation per day with feed thickeners and that the authors reported a reduction of two episodes of regurgitation per day may be clinically significant to caregivers. The Committee considered this evidence showed a potential for use of food thickeners in infants and reflected clinical practice; however acknowledged that regurgitation was a self-resolving phenomenon in this population.</p><p class=""ql-indent-2""><br></p><p>The Committee also noted the following evidence:</p><p class=""ql-indent-2""><br></p><ul><li>O’Keeffe et al. BMC Geriatr. 2018;18:167</li><li>Lippert et al. J Hosp Med. 2019;14:315-7</li><li>Wallis et al. Pediatr Allergy Immunol Pulmonol. 2012;25:132-42</li><li>Duncan et al. Curr Gastroenterol Rep. 2019;21:30</li><li>Leder et al. Dysphagia. 2013;28:58-62</li><li>Das et al. UpToDate. 2020. Accessed 22 April 2021.</li><li>Duncan et al. Curr Gastroenterol Rep. 2019;21:30</li><li>Ramakrishnam et al. Curr Gastroenterol Rep. 2002;4:218-24.</li><li>Duncan et al. J Pediatr Gastroenterol Nutr. 2019;68:218-24.</li><li>Gurberg et al. Int J Pediatr Otorhinolaryngol. 2015;79:1827-30</li><li>Piccione et al. Pediatr Pulmonl. 2012;47:447-52</li><li>Steele et al. Dysphagia. 2015;30:2-2</li><li>Diniz et al. Nutr Clin Pract. 2009;24:414-8</li><li>Robbins et al. Ann Intern Med. 2008;148:509-18</li><li>Ozaki et al. Tohoku J Exp Med. 2010;220:41-6</li><li>Foley et al. Age Ageing. 2008;37:258-64</li><li>Campbell-Taylor, I. J Am Med Dir Assoc. 2008;9:523-31</li><li>Coyle et al. J Am Med Dir Assoc. 2009;10:62-6; discussion 79-83</li><li>Horvath et al. Pediatrics. 2008;122:e1268-77</li><li>Huang et al. Cochrane Database Syst Rev. 2002;(3):CD003211</li><li>Garcia et al. Nutr Hosp. 2015;31 Suppl 5:56-66</li><li>Jesus et al. Amyotroph Lateral Scler. 2012;13:538-43</li><li>Pezzana et al. J Nutr Health Aging. 2015;19:947-54</li><li>Rofes et al. Gut. 2013;62:1280-7</li><li>Wright et al. Geriatrics (Basel). 2020;5:9</li><li>Sukkar et al. Front Nutr. 2018 7;5:68</li><li>Hwang et al. Ann Rehabil Med. 2017;41:9-15</li><li>Trelis et al. Nutr Hosp. 2002;17:168-74</li><li> Vilardell et al. Dysphagia. 2016;31:169-79</li><li>Sezgin et al. Eur Arch Otorhinolaryngol. 2018;275:2997-3005</li><li>Miranda et al. Nutr Clin Pract. 2020;35:649-54</li><li>Tomita et al. Dysphagia. 2017;32:449-53</li><li>Tomita et al. Yakugaku Zasshi. 2016;136:1171-6</li></ul><p class=""ql-indent-2""><br></p><p>The Committee considered that the evidence for food thickeners does not support wider use in practice, that there is a lack of good quality evidence that thickening liquids reduces pneumonia in dysphagia, and that there is some risk that food thickeners may be associated with reduced fluid intake, undernutrition and potential reduction in quality of life. The Committee considered that the use of food thickeners in practice was often based on expert clinical opinion, in the absence of good quality evidence that all patients with dysphagia would benefit from food thickeners.</p><p><br></p><p>Members considered that thickened fluids may not be in the best interest of all patients in some cases other forms of supportive palliative care for symptom management may be more appropriate. Members also considered that thickened fluids can increase the risk of pneumonia in patients with vocal cord dysfunction who cannot effectively protect their airway and may aspirate thickened fluids. Members considered that patients with severe dysphagia remained at risk of silently aspirating at times when not consuming food and fluids, regardless of the use of thickened products.</p><p><br></p><p>Overall, the Committee considered that the evidence base for food thickeners in dysphagia included poor quality evidence with differing assessments of this evidence by different professional groups (Campbell-Taylor I. 2008; Coyle et al. 2009; O’Keeffe et al. 2018; Lippert et al. 2019). Members considered that reasonable quality evidence could be expected in this setting, given the high prevalence of dysphagia across age groups and disease types.</p><p><br></p><p><i>General</i> </p><p><br></p><p>The Committee acknowledged the clinical input provided in response to Pharmac’s request for information and recognised the feedback regarding the inconsistency in access to food thickeners in the community and equity concerns associated with this. The Committee noted that there were likely further inequities due to regional variation in access to Speech-Language Therapists.</p><p><br></p><p>The Committee considered that there was a large potential clinical group with health need due to dysphagia but that this group was hard to define, and additionally that it was not possible to identify a population with the greatest need who could be targeted by funded treatment. The Committee considered that this presented significant fiscal risk with little to no evidence of clinical benefit and evidence of potential net harm.</p><p><br></p><p>The Committee acknowledged the high health need of people with dysphagia but noted that there is no evidence that food thickeners would address the unmet need of patients with dysphagia and some evidence that food thickeners may worsen health outcomes and lead to harm. The Committee reiterated its previous recommendation and support to delist food thickeners from the community funding schedule.\xa0\xa0</p><p><br></p><p>\xa0</p>', 'Status_History__c': 'a132P000000D6TAQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwV2AS'}, 'Id': 'a0POZ000004AlwV2AS', 'Event_Date__c': '2023-07-11', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000FXS9QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 18 August 2023', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 18 August 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwW2AS'}, 'Id': 'a0POZ000004AlwW2AS', 'Event_Date__c': '2023-07-31', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 18 August 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a13OZ00000186uCYAQ'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> that access to funded food thickeners be retained in the community for people with motor neurone disease with a swallowing disorder.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Considered the health need of people with motor neurone disease with a swallowing disorder and their caregivers/family/whānau, and the benefits and risks of food thickeners versus other available treatments and timing of treatments (including earlier insertion of PEG or similar surgical interventions for progressive dysphagia).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted that food thickeners have been available and funded in New Zealand for the management of dysphagia for people with motor neurone disease in the community for a number of years, and that their use is an established and long-standing aspect of clinical practice, which is supported by New Zealand and international clinical guidelines.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted there have been no randomised clinical trials undertaken to evaluate the benefit of food thickeners specifically for people with motor neurone disease or other groups of people with persistent and progressive swallowing disorders.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted that specific clinical trials have been undertaken in populations with dysphagia due to causes, such as stroke, that may stabilise or improve over time and considered that as these trials suggest there is no benefit associated with the use of food thickeners for these groups, widened access to these population groups cannot be supported at this time.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Considered that people with persistent and progressive swallowing disorders would have a similar health need to people with motor neurone disease who have a swallowing disorder with respect to their swallowing and its health impact.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Reiterated its concerns around the risk of harm from the longer-term use of food thickeners in people without progressive dysphagia.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee considered<strong> </strong>that further work needed to be undertaken by Pharmac to better define the groups of people with persistent and progressive swallowing disorders, who would be considered to have an equivalent health need to the currently funded group with motor neurone disease.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered it was likely this would include people with persistent and progressive swallowing disorders that lead to significant weight loss where surgical interventions such as a percutaneous endoscopic gastrostomy (PEG) are indicated to meet nutritional and/or hydration requirements, or people with similar presentations where PEG insertion is not possible.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> that access to funded food thickeners be retained in the community for people with motor neurone disease with a swallowing disorder.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Considered the health need of people with motor neurone disease with a swallowing disorder and their caregivers/family/whānau, and the benefits and risks of food thickeners versus other available treatments and timing of treatments (including earlier insertion of PEG or similar surgical interventions for progressive dysphagia).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted that food thickeners have been available and funded in New Zealand for the management of dysphagia for people with motor neurone disease in the community for a number of years, and that their use is an established and long-standing aspect of clinical practice, which is supported by New Zealand and international clinical guidelines.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted there have been no randomised clinical trials undertaken to evaluate the benefit of food thickeners specifically for people with motor neurone disease or other groups of people with persistent and progressive swallowing disorders.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted that specific clinical trials have been undertaken in populations with dysphagia due to causes, such as stroke, that may stabilise or improve over time and considered that as these trials suggest there is no benefit associated with the use of food thickeners for these groups, widened access to these population groups cannot be supported at this time.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Considered that people with persistent and progressive swallowing disorders would have a similar health need to people with motor neurone disease who have a swallowing disorder with respect to their swallowing and its health impact.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Reiterated its concerns around the risk of harm from the longer-term use of food thickeners in people without progressive dysphagia.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee considered<strong> </strong>that further work needed to be undertaken by Pharmac to better define the groups of people with persistent and progressive swallowing disorders, who would be considered to have an equivalent health need to the currently funded group with motor neurone disease.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered it was likely this would include people with persistent and progressive swallowing disorders that lead to significant weight loss where surgical interventions such as a percutaneous endoscopic gastrostomy (PEG) are indicated to meet nutritional and/or hydration requirements, or people with similar presentations where PEG insertion is not possible.</p>', 'change': None}, 'Published_Discussion': {'s': '<h2><em>Māori impact</em></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding food thickeners in the community for people with persistent and progressive swallowing disorders, including motor neurone disease on Māori health areas of focus and Māori health outcomes. The Committee noted that persistent and progressive swallowing disorders were not specifically identified as a Māori health area of focus and were not expected to impact Māori at higher rates than other population groups in New Zealand, although information regarding this was not readily available due to the small numbers of people expected.</p><h2><em>Impact on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system</em></h2><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there was a lack of evidence to assess the impact of funding food thickeners in the community for people with persistent and progressive swallowing disorders among Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system.</p><h2><em>Background</em></h2><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in February 2023 Pharmac had released a public <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"" style=""color: windowtext;"">consultation on a proposal</a> to phase out the funding of food thickeners\xa0in the community. The Committee noted that the vast majority of the responses received did not support Pharmac’s proposal and requested that access to food thickeners in the community be retained and widened to include people with dysphagia due to causes other than motor neurone disease.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee noted the responses to the consultation. The Committee appreciated and valued the information shared by Motor Neurone Disease NZ regarding the health need and lived experience of people with motor neurone disease in New Zealand and the use of food thickeners to help manage their condition.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the extensive history of clinical advice from PTAC and Pharmac’s Specialist Advisory Committees (previously PTAC Subcommittees) for the use of food thickeners in the community. The Committee noted that PTAC had most recently considered the <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">funding of food thickeners in the community in 2021</a> following the release of a Request For Information by Pharmac.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that two brands of food thickeners were currently funded for use in hospital and in the community for people with dysphagia (swallowing difficulties), with community funding restricted to people with motor neurone disease with a swallowing disorder. The Committee noted that this restricted community funding was inconsistent with clinical practice, as dysphagia can occur in conditions other than motor neurone disease.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the rationale for funding food thickeners in the community for people with motor neurone disease with swallowing disorder (and not funding for other causes of dysphagia/swallowing disorder) is not apparent and appears to have arisen shortly after the establishment of Pharmac.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the inconsistent funding of food thickeners in the community had resulted in a complaint to the Human Rights Commission (HRC) alleging discrimination on the basis of disability. This complaint was on the grounds that food thickeners in the community are currently funded for one group of people with a particular underlying condition, and not for people with different underlying conditions, even though both groups were said to require the product to address the same health need– namely dysphagia.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">2021</a> PTAC had considered a range of information regarding the funding of food thickeners in the community, and that the purpose of the present discussion\xa0was to consider any new information not considered already in 2021, and to consider the responses to the <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">February 2023 consultation</a>.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in 2021 it had also <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">confirmed its previous recommendation</a>\xa0that the community funding of food thickeners be delisted from the Pharmaceutical Schedule as there was insufficient evidence that food thickeners would be expected to address the unmet needs and provide clinically meaningful benefits for people with dysphagia. Additionally, the Committee had noted there is some evidence of a risk of harm from use of food thickeners in dysphagia, and it would be difficult to define a specific population that may benefit from food thickeners.</p><h2><em>Health need</em></h2><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there were a large number of conditions that could result in dysphagia. The Committee considered that people with dysphagia could be split into two groups. The first group is people with dysphagia that stabilises or improves over time. The second group experiences persistent and progressive dysphagia that worsens with time, frequently caused by underlying diseases causing lifespans that are time-limited, and leads to significant weight loss and/or dehydration, and the recommendation of surgical interventions such as a percutaneous endoscopic gastrostomy (PEG) to meet nutritional/hydration requirements. The Committee considered that the latter group would have a higher health need than other people with dysphagia. The Committee considered that this group would include people with bulbar and pseudo bulbar palsy, including but not limited to, people with motor neurone disease, people with advanced Parkinson’s disease, people with advanced multiple sclerosis, and people with Huntington’s disease.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the number of people in this group would be small and the majority would be included in the currently eligible group of people with motor neurone disease.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered further work would need to be undertaken by Pharmac staff, including engagement with relevant specialists, to clearly define the group of people with persistent and progressive dysphagia in New Zealand, and to determine whether any widening of access criteria is required to include all people in this group.,.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that coughing and choking while eating and drinking is uncomfortable and distressing for people with persistent and progressive dysphagia, their whānau, and caregivers.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the people with persistent and progressive dysphagia with the highest health need would require feeding via a PEG or other similar surgically placed interventions as their dysphagia worsened. The Committee noted that there would be a subset of this group who are unable to receive a PEG, or similar intervention, due to deteriorating respiratory function and significant perioperative risk. .</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered there was currently a high unmet need for people with persistent and progressive dysphagia, and noted there was often no cure for the underlying cause of their dysphagia and they typically have very short life expectancies. The Committee considered that due to this high unmet health need, even a small improvement in quality of life could have a pressing and meaningful impact.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members discussed whether, the threshold of evidence for ongoing funding in the community of any pharmaceutical might differ from the evidentiary threshold for widening of access of any pharmaceutical to new population groups or funding a novel treatment. Members considered the latter might be expected to better demonstrate evidence of benefit.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that people with motor neurone disease and the clinicians may consider that any removal of funding of food thickeners in the community would increase their health need.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted information from Motor Neurone Disease NZ that due to the rapidly progressive nature of their disease, people with motor neurone disease in New Zealand typically receive food thickeners for a period of 6 months, with a small number of people receiving food thickeners for up to 12 months.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in addition to food thickeners other options are available to help people manage their dysphagia such as using the chin down technique when swallowing, pacing when eating and drinking, posture, and pureed food, however these techniques are unlikely to fully resolve a person’s dysphagia.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that people with dysphagia would typically be cared for by a multidisciplinary team, including Speech Language Therapists who advise on appropriate options including the use of food thickeners.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that video-fluoroscopic swallowing studies (VFSS) are often requested by Speech Language Therapists to establish a diagnosis and demonstrate aspiration. Liquids of different thickness can be evaluated via VSS to determine whether thickening reduces aspiration.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that the thickening of fluids and foods to reduce aspiration would not reduce aspiration occurring outside of eating and drinking.</p><h2><em>Health Benefit</em></h2><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee recalled the evidence it had reviewed as part of its February 2021 consideration of the community funding of food thickeners.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered research that had become available since its February 2021 review of food thickeners, as well as information it had not considered in 2021, including the following:</p><p class=""ql-indent-1"">1.25.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291955/"" target=""_blank"">Steele et al. Breathe 2021;17:210003</a></p><p class=""ql-indent-1"">This review of the evidence for thickened fluids in the management of dysphagia concluded that there is no evidence to support the clinical benefits of thickened fluids in the treatment of dysphagia. In addition, there was some evidence that thickened fluids are a poorly tolerated intervention associated with lower health related quality of life and increased risks of malnutrition and dehydration.</p><p class=""ql-indent-1"">1.25.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28730887/"" target=""_blank"">Kaneoka et al. Clin Rehabil 2017;31:1116-25</a></p><p class=""ql-indent-1"">A systematic review and meta-analysis of published or unpublished randomised controlled trials and prospective non-randomised trials comparing the incidence of pneumonia with intake of thin liquids plus safety strategies vs thickened liquids in adult patients who have previously aspirated on thin liquids. This concluded that amongst patients with a low risk of pneumonia there was no significant difference in the risk of pneumonia in patients who took thin liquids with safety strategies compared with those who took thickened liquids only (odds ratio (OR) 0.82, 95% CI 0.05-13.42, p = 0.89).</p><p class=""ql-indent-1"">1.25.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509132/"" target=""_blank"">Ahn et al. Medicine (Baltimore). 2022;101(38)</a></p><p class=""ql-indent-1"">This observational pilot study investigated the status of thickener use in twenty dysphagia patients with brain lesions and then measured the incidence of adverse events based on fluid viscosity. Forty percent of the cases did not successfully formulate their thickener to correct viscosity, as trained.</p><p class=""ql-indent-1"">1.25.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.frontiersin.org/articles/10.3389/fneur.2017.00094/full"" target=""_blank"">Onesti et al. Front Neurol. 2017; 8:94</a></p><p class=""ql-indent-1"">A retrospective study conducted over a two year period which aimed to investigate the clinical features associated with deteriorated swallow in one hundred forty-five people with amyotrophic lateral sclerosis (ALS) with spinal and bulbar onset and describe the modification of diet and liquid intake. The study concluded that the frequency of use of normal and semi-solid diets decreased over time, while that of pureed diets and PEG prescription increased. Forty-four percent of dysphagic patients refused thickeners or PEG.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of international clinical guidelines on use of thickened fluids for dysphagia post stroke, which the Committee had reviewed in May 2021, which noted 13 clinical guidelines were available and, despite the lack of clinical evidence available the consensus statements were\xa0that thickened fluids were recommended (<a href=""https://onlinelibrary.wiley.com/doi/10.1111/jep.13372"" target=""_blank"">McCurtin et al. J Eval Clin Pract. 2020;26:1744-60</a>)</p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was no new primary research or clinical trial evidence or food thickeners in dysphagia, including dysphagia in motor neurone disease, and that newly published systematic reviews included previously reviewed primary evidence. The Committee considered that there was no new evidence to support the benefits from food thickeners.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Overall, the Committee considered that the evidence available did not support the use of food thickeners for the management of dysphagia.</p><p><span style=""color: black;"">1.29.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted references to the use of food thickeners were included in the <a href=""https://mnd.org.nz/wp-content/uploads/2022/11/NZ-Best-Practice-Recommendations-For-The-Care-Of-People-With-MND-issue-1-November-2022-FINAL.pdf"" target=""_blank"">New Zealand Best Practice Recommendations for people with Motor Neurone Disease</a>, which were produced by Motor Neurone Disease New Zealand.</p><p><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there were a very limited number of high-quality trials that had been undertaken to evaluate the benefit associated with food thickeners and considered that none of these trials reported any benefit associated with the use of food thickeners in the management of dysphagia.</p><p class=""ql-indent-1"">1.30.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that these trials had been undertaken in populations with dysphagia from a range of causes and severities, and none of them included people with motor neurone disease or other similar groups with persistent and progressive dysphagia.</p><p class=""ql-indent-1"">1.30.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In addition, the Committee considered the endpoints investigated in the studies, such as a reduction in aspiration pneumonia and overall improvements in quality of life, may miss a small group of people with dysphagia who are receiving some benefit from the use of food thickeners.</p><p><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the use of food thickeners in the management of dysphagia was an established and long-standing aspect of clinical practice in New Zealand. The Committee noted that any recommendation to remove funded food thickeners from the community would be contrary to international guidelines for the management of dysphagia, noting again however the apparent paucity of clinical evidence supporting guidelines’ recommendations (<a href=""https://onlinelibrary.wiley.com/doi/10.1111/jep.13372"" target=""_blank"">McCurtin et al. 2020</a>).</p><p><span style=""color: black;"">1.32.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was evidence that the inappropriate use of food thickeners could result in harm, including malnourishment or dehydration. The Committee also noted that the ongoing availability of food thickeners in the community could possibly lead to people missing out on the window of opportunity to receive a PEG insertion, resulting in poorer health outcomes. However, the Committee considered any incidence of this would be limited and members were not aware of this arising in clinical practice.</p><h2><em>Suitability </em></h2><p><span style=""color: black;"">1.33.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted feedback received in response to Pharmac’s February 2023 consultation, that the two brands of food thickener funded by Pharmac were not preferred in the management of dysphagia as they are starch based thickeners, which can result in a grainy or lumpy texture, compared to thickeners made from other agents such as xanthan gum or guar gum.</p><p><span style=""color: black;"">1.34.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the thickeners that are currently funded by Pharmac were supplied as a powder and needed to be mixed by the person with dysphagia or their carers, which could make reliably achieving a desired viscosity challenging.</p><p><span style=""color: black;"">1.35.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that some people would not be able to afford other types of preferred thickener and these people were likely to be accessing the currently funded products.</p><p><span style=""color: black;"">1.36.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that premixed, thickened fluids were available, which could avoid the issues with texture and viscosity associated with the currently available thickeners. The Committee was unsure if premixed, thickened fluids would be preferred by people with dysphagia, as they could not be mixed with food or beverages the person already enjoyed.</p><p><span style=""color: black;"">1.37.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that many people with dysphagia who were recommended to use a thickener did not like using them and chose to continue consuming unthickened food and fluids.</p><p><span style=""color: black;"">1.38.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that the ongoing availability of food thickeners in the community could allow for a more individualised approach to be taken to the management of dysphagia than if they were not available.</p><h2><em>Costs and savings </em></h2><p><span style=""color: black;"">1.39.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that, based on current pricing, the per unit cost associated with funded food thickeners was relatively low and would be estimated to cost $364 per person per year assuming 26 cans were used each year.</p><p><span style=""color: black;"">1.40.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that if the access was widened to include all people with dysphagia, the cost to the Combined Pharmaceutical Budget could be substantial.</p><h2><em>General </em></h2><p><span style=""color: black;"">1.41.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee did not consider it would be appropriate to include an assessment by a Speech Language Therapist in any Special Authority criteria for access to food thickeners in the community, because access to Speech Language Therapists was unlikely to be equitable across the country and could present a barrier to access for some people. In addition, it was noted that even if people were able to access a Speech Language Therapist, access to video-fluoroscopic swallowing studies was unlikely to be available to all people in New Zealand.</p><p><span style=""color: black;"">1.42.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was evidence to support the use of PEG feeding in the management of dysphagia, and positive health outcomes associated with this. The Committee considered it would be supportive of greater access to PEG insertions for people with dysphagia. It was noted that this would be dependent on the availability of relevant surgical time and resource which may not be available across regions.</p><p><span style=""color: black;"">1.43.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee reiterated its concerns around the risk of harm from the longer-term use of food thickeners in people without progressive disease.</p><h2><em>Summary for assessment</em></h2><p><span style=""color: black;"">1.44.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for food thickeners if they are to continue to be funded in New Zealand for </span>people with persistent and progressive swallowing disorders, including motor neurone disease.<span style=""color: black;""> This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004AlwX&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000Tnv1"" alt=""image.png""></img></p>', 'fs': '<h2><em>Māori impact</em></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding food thickeners in the community for people with persistent and progressive swallowing disorders, including motor neurone disease on Māori health areas of focus and Māori health outcomes. The Committee noted that persistent and progressive swallowing disorders were not specifically identified as a Māori health area of focus and were not expected to impact Māori at higher rates than other population groups in New Zealand, although information regarding this was not readily available due to the small numbers of people expected.</p><h2><em>Impact on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system</em></h2><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there was a lack of evidence to assess the impact of funding food thickeners in the community for people with persistent and progressive swallowing disorders among Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system.</p><h2><em>Background</em></h2><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in February 2023 Pharmac had released a public <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"" style=""color: windowtext;"">consultation on a proposal</a> to phase out the funding of food thickeners\xa0in the community. The Committee noted that the vast majority of the responses received did not support Pharmac’s proposal and requested that access to food thickeners in the community be retained and widened to include people with dysphagia due to causes other than motor neurone disease.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee noted the responses to the consultation. The Committee appreciated and valued the information shared by Motor Neurone Disease NZ regarding the health need and lived experience of people with motor neurone disease in New Zealand and the use of food thickeners to help manage their condition.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the extensive history of clinical advice from PTAC and Pharmac’s Specialist Advisory Committees (previously PTAC Subcommittees) for the use of food thickeners in the community. The Committee noted that PTAC had most recently considered the <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">funding of food thickeners in the community in 2021</a> following the release of a Request For Information by Pharmac.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that two brands of food thickeners were currently funded for use in hospital and in the community for people with dysphagia (swallowing difficulties), with community funding restricted to people with motor neurone disease with a swallowing disorder. The Committee noted that this restricted community funding was inconsistent with clinical practice, as dysphagia can occur in conditions other than motor neurone disease.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the rationale for funding food thickeners in the community for people with motor neurone disease with swallowing disorder (and not funding for other causes of dysphagia/swallowing disorder) is not apparent and appears to have arisen shortly after the establishment of Pharmac.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the inconsistent funding of food thickeners in the community had resulted in a complaint to the Human Rights Commission (HRC) alleging discrimination on the basis of disability. This complaint was on the grounds that food thickeners in the community are currently funded for one group of people with a particular underlying condition, and not for people with different underlying conditions, even though both groups were said to require the product to address the same health need– namely dysphagia.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">2021</a> PTAC had considered a range of information regarding the funding of food thickeners in the community, and that the purpose of the present discussion\xa0was to consider any new information not considered already in 2021, and to consider the responses to the <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">February 2023 consultation</a>.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in 2021 it had also <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">confirmed its previous recommendation</a>\xa0that the community funding of food thickeners be delisted from the Pharmaceutical Schedule as there was insufficient evidence that food thickeners would be expected to address the unmet needs and provide clinically meaningful benefits for people with dysphagia. Additionally, the Committee had noted there is some evidence of a risk of harm from use of food thickeners in dysphagia, and it would be difficult to define a specific population that may benefit from food thickeners.</p><h2><em>Health need</em></h2><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there were a large number of conditions that could result in dysphagia. The Committee considered that people with dysphagia could be split into two groups. The first group is people with dysphagia that stabilises or improves over time. The second group experiences persistent and progressive dysphagia that worsens with time, frequently caused by underlying diseases causing lifespans that are time-limited, and leads to significant weight loss and/or dehydration, and the recommendation of surgical interventions such as a percutaneous endoscopic gastrostomy (PEG) to meet nutritional/hydration requirements. The Committee considered that the latter group would have a higher health need than other people with dysphagia. The Committee considered that this group would include people with bulbar and pseudo bulbar palsy, including but not limited to, people with motor neurone disease, people with advanced Parkinson’s disease, people with advanced multiple sclerosis, and people with Huntington’s disease.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the number of people in this group would be small and the majority would be included in the currently eligible group of people with motor neurone disease.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered further work would need to be undertaken by Pharmac staff, including engagement with relevant specialists, to clearly define the group of people with persistent and progressive dysphagia in New Zealand, and to determine whether any widening of access criteria is required to include all people in this group.,.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that coughing and choking while eating and drinking is uncomfortable and distressing for people with persistent and progressive dysphagia, their whānau, and caregivers.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the people with persistent and progressive dysphagia with the highest health need would require feeding via a PEG or other similar surgically placed interventions as their dysphagia worsened. The Committee noted that there would be a subset of this group who are unable to receive a PEG, or similar intervention, due to deteriorating respiratory function and significant perioperative risk. .</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered there was currently a high unmet need for people with persistent and progressive dysphagia, and noted there was often no cure for the underlying cause of their dysphagia and they typically have very short life expectancies. The Committee considered that due to this high unmet health need, even a small improvement in quality of life could have a pressing and meaningful impact.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members discussed whether, the threshold of evidence for ongoing funding in the community of any pharmaceutical might differ from the evidentiary threshold for widening of access of any pharmaceutical to new population groups or funding a novel treatment. Members considered the latter might be expected to better demonstrate evidence of benefit.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that people with motor neurone disease and the clinicians may consider that any removal of funding of food thickeners in the community would increase their health need.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted information from Motor Neurone Disease NZ that due to the rapidly progressive nature of their disease, people with motor neurone disease in New Zealand typically receive food thickeners for a period of 6 months, with a small number of people receiving food thickeners for up to 12 months.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in addition to food thickeners other options are available to help people manage their dysphagia such as using the chin down technique when swallowing, pacing when eating and drinking, posture, and pureed food, however these techniques are unlikely to fully resolve a person’s dysphagia.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that people with dysphagia would typically be cared for by a multidisciplinary team, including Speech Language Therapists who advise on appropriate options including the use of food thickeners.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that video-fluoroscopic swallowing studies (VFSS) are often requested by Speech Language Therapists to establish a diagnosis and demonstrate aspiration. Liquids of different thickness can be evaluated via VSS to determine whether thickening reduces aspiration.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that the thickening of fluids and foods to reduce aspiration would not reduce aspiration occurring outside of eating and drinking.</p><h2><em>Health Benefit</em></h2><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee recalled the evidence it had reviewed as part of its February 2021 consideration of the community funding of food thickeners.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered research that had become available since its February 2021 review of food thickeners, as well as information it had not considered in 2021, including the following:</p><p class=""ql-indent-1"">1.25.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291955/"" target=""_blank"">Steele et al. Breathe 2021;17:210003</a></p><p class=""ql-indent-1"">This review of the evidence for thickened fluids in the management of dysphagia concluded that there is no evidence to support the clinical benefits of thickened fluids in the treatment of dysphagia. In addition, there was some evidence that thickened fluids are a poorly tolerated intervention associated with lower health related quality of life and increased risks of malnutrition and dehydration.</p><p class=""ql-indent-1"">1.25.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28730887/"" target=""_blank"">Kaneoka et al. Clin Rehabil 2017;31:1116-25</a></p><p class=""ql-indent-1"">A systematic review and meta-analysis of published or unpublished randomised controlled trials and prospective non-randomised trials comparing the incidence of pneumonia with intake of thin liquids plus safety strategies vs thickened liquids in adult patients who have previously aspirated on thin liquids. This concluded that amongst patients with a low risk of pneumonia there was no significant difference in the risk of pneumonia in patients who took thin liquids with safety strategies compared with those who took thickened liquids only (odds ratio (OR) 0.82, 95% CI 0.05-13.42, p = 0.89).</p><p class=""ql-indent-1"">1.25.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509132/"" target=""_blank"">Ahn et al. Medicine (Baltimore). 2022;101(38)</a></p><p class=""ql-indent-1"">This observational pilot study investigated the status of thickener use in twenty dysphagia patients with brain lesions and then measured the incidence of adverse events based on fluid viscosity. Forty percent of the cases did not successfully formulate their thickener to correct viscosity, as trained.</p><p class=""ql-indent-1"">1.25.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.frontiersin.org/articles/10.3389/fneur.2017.00094/full"" target=""_blank"">Onesti et al. Front Neurol. 2017; 8:94</a></p><p class=""ql-indent-1"">A retrospective study conducted over a two year period which aimed to investigate the clinical features associated with deteriorated swallow in one hundred forty-five people with amyotrophic lateral sclerosis (ALS) with spinal and bulbar onset and describe the modification of diet and liquid intake. The study concluded that the frequency of use of normal and semi-solid diets decreased over time, while that of pureed diets and PEG prescription increased. Forty-four percent of dysphagic patients refused thickeners or PEG.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of international clinical guidelines on use of thickened fluids for dysphagia post stroke, which the Committee had reviewed in May 2021, which noted 13 clinical guidelines were available and, despite the lack of clinical evidence available the consensus statements were\xa0that thickened fluids were recommended (<a href=""https://onlinelibrary.wiley.com/doi/10.1111/jep.13372"" target=""_blank"">McCurtin et al. J Eval Clin Pract. 2020;26:1744-60</a>)</p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was no new primary research or clinical trial evidence or food thickeners in dysphagia, including dysphagia in motor neurone disease, and that newly published systematic reviews included previously reviewed primary evidence. The Committee considered that there was no new evidence to support the benefits from food thickeners.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Overall, the Committee considered that the evidence available did not support the use of food thickeners for the management of dysphagia.</p><p><span style=""color: black;"">1.29.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted references to the use of food thickeners were included in the <a href=""https://mnd.org.nz/wp-content/uploads/2022/11/NZ-Best-Practice-Recommendations-For-The-Care-Of-People-With-MND-issue-1-November-2022-FINAL.pdf"" target=""_blank"">New Zealand Best Practice Recommendations for people with Motor Neurone Disease</a>, which were produced by Motor Neurone Disease New Zealand.</p><p><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there were a very limited number of high-quality trials that had been undertaken to evaluate the benefit associated with food thickeners and considered that none of these trials reported any benefit associated with the use of food thickeners in the management of dysphagia.</p><p class=""ql-indent-1"">1.30.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that these trials had been undertaken in populations with dysphagia from a range of causes and severities, and none of them included people with motor neurone disease or other similar groups with persistent and progressive dysphagia.</p><p class=""ql-indent-1"">1.30.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In addition, the Committee considered the endpoints investigated in the studies, such as a reduction in aspiration pneumonia and overall improvements in quality of life, may miss a small group of people with dysphagia who are receiving some benefit from the use of food thickeners.</p><p><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the use of food thickeners in the management of dysphagia was an established and long-standing aspect of clinical practice in New Zealand. The Committee noted that any recommendation to remove funded food thickeners from the community would be contrary to international guidelines for the management of dysphagia, noting again however the apparent paucity of clinical evidence supporting guidelines’ recommendations (<a href=""https://onlinelibrary.wiley.com/doi/10.1111/jep.13372"" target=""_blank"">McCurtin et al. 2020</a>).</p><p><span style=""color: black;"">1.32.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was evidence that the inappropriate use of food thickeners could result in harm, including malnourishment or dehydration. The Committee also noted that the ongoing availability of food thickeners in the community could possibly lead to people missing out on the window of opportunity to receive a PEG insertion, resulting in poorer health outcomes. However, the Committee considered any incidence of this would be limited and members were not aware of this arising in clinical practice.</p><h2><em>Suitability </em></h2><p><span style=""color: black;"">1.33.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted feedback received in response to Pharmac’s February 2023 consultation, that the two brands of food thickener funded by Pharmac were not preferred in the management of dysphagia as they are starch based thickeners, which can result in a grainy or lumpy texture, compared to thickeners made from other agents such as xanthan gum or guar gum.</p><p><span style=""color: black;"">1.34.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the thickeners that are currently funded by Pharmac were supplied as a powder and needed to be mixed by the person with dysphagia or their carers, which could make reliably achieving a desired viscosity challenging.</p><p><span style=""color: black;"">1.35.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that some people would not be able to afford other types of preferred thickener and these people were likely to be accessing the currently funded products.</p><p><span style=""color: black;"">1.36.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that premixed, thickened fluids were available, which could avoid the issues with texture and viscosity associated with the currently available thickeners. The Committee was unsure if premixed, thickened fluids would be preferred by people with dysphagia, as they could not be mixed with food or beverages the person already enjoyed.</p><p><span style=""color: black;"">1.37.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that many people with dysphagia who were recommended to use a thickener did not like using them and chose to continue consuming unthickened food and fluids.</p><p><span style=""color: black;"">1.38.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that the ongoing availability of food thickeners in the community could allow for a more individualised approach to be taken to the management of dysphagia than if they were not available.</p><h2><em>Costs and savings </em></h2><p><span style=""color: black;"">1.39.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that, based on current pricing, the per unit cost associated with funded food thickeners was relatively low and would be estimated to cost $364 per person per year assuming 26 cans were used each year.</p><p><span style=""color: black;"">1.40.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that if the access was widened to include all people with dysphagia, the cost to the Combined Pharmaceutical Budget could be substantial.</p><h2><em>General </em></h2><p><span style=""color: black;"">1.41.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee did not consider it would be appropriate to include an assessment by a Speech Language Therapist in any Special Authority criteria for access to food thickeners in the community, because access to Speech Language Therapists was unlikely to be equitable across the country and could present a barrier to access for some people. In addition, it was noted that even if people were able to access a Speech Language Therapist, access to video-fluoroscopic swallowing studies was unlikely to be available to all people in New Zealand.</p><p><span style=""color: black;"">1.42.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was evidence to support the use of PEG feeding in the management of dysphagia, and positive health outcomes associated with this. The Committee considered it would be supportive of greater access to PEG insertions for people with dysphagia. It was noted that this would be dependent on the availability of relevant surgical time and resource which may not be available across regions.</p><p><span style=""color: black;"">1.43.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee reiterated its concerns around the risk of harm from the longer-term use of food thickeners in people without progressive disease.</p><h2><em>Summary for assessment</em></h2><p><span style=""color: black;"">1.44.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for food thickeners if they are to continue to be funded in New Zealand for </span>people with persistent and progressive swallowing disorders, including motor neurone disease.<span style=""color: black;""> This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004AlwX&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000Tnv1"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the funding of food thickeners following\xa0Pharmac’s <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"">February 2023 consultation</a> to phase out funding of food thickeners in the community.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee viewed a presentation from Motor Neurone Disease NZ, highlighting the health need of people with motor neurone disease in New Zealand and the benefit offered by food thickeners for people with motor neurone disease living in the community.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the funding of food thickeners following\xa0Pharmac’s <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"">February 2023 consultation</a> to phase out funding of food thickeners in the community.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee viewed a presentation from Motor Neurone Disease NZ, highlighting the health need of people with motor neurone disease in New Zealand and the benefit offered by food thickeners for people with motor neurone disease living in the community.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 18 August 2023.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 18 August 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwX2AS'}, 'Id': 'a0POZ000004AlwX2AS', 'Event_Date__c': '2023-11-03', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 18 August 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Nov 2023', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> that access to funded food thickeners be retained in the community for people with motor neurone disease with a swallowing disorder.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Considered the health need of people with motor neurone disease with a swallowing disorder and their caregivers/family/whānau, and the benefits and risks of food thickeners versus other available treatments and timing of treatments (including earlier insertion of PEG or similar surgical interventions for progressive dysphagia).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted that food thickeners have been available and funded in New Zealand for the management of dysphagia for people with motor neurone disease in the community for a number of years, and that their use is an established and long-standing aspect of clinical practice, which is supported by New Zealand and international clinical guidelines.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted there have been no randomised clinical trials undertaken to evaluate the benefit of food thickeners specifically for people with motor neurone disease or other groups of people with persistent and progressive swallowing disorders.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noted that specific clinical trials have been undertaken in populations with dysphagia due to causes, such as stroke, that may stabilise or improve over time and considered that as these trials suggest there is no benefit associated with the use of food thickeners for these groups, widened access to these population groups cannot be supported at this time.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Considered that people with persistent and progressive swallowing disorders would have a similar health need to people with motor neurone disease who have a swallowing disorder with respect to their swallowing and its health impact.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Reiterated its concerns around the risk of harm from the longer-term use of food thickeners in people without progressive dysphagia.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee considered<strong> </strong>that further work needed to be undertaken by Pharmac to better define the groups of people with persistent and progressive swallowing disorders, who would be considered to have an equivalent health need to the currently funded group with motor neurone disease.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered it was likely this would include people with persistent and progressive swallowing disorders that lead to significant weight loss where surgical interventions such as a percutaneous endoscopic gastrostomy (PEG) are indicated to meet nutritional and/or hydration requirements, or people with similar presentations where PEG insertion is not possible.</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the funding of food thickeners following\xa0Pharmac’s <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"">February 2023 consultation</a> to phase out funding of food thickeners in the community.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee viewed a presentation from Motor Neurone Disease NZ, highlighting the health need of people with motor neurone disease in New Zealand and the benefit offered by food thickeners for people with motor neurone disease living in the community.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h2><em>Māori impact</em></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding food thickeners in the community for people with persistent and progressive swallowing disorders, including motor neurone disease on Māori health areas of focus and Māori health outcomes. The Committee noted that persistent and progressive swallowing disorders were not specifically identified as a Māori health area of focus and were not expected to impact Māori at higher rates than other population groups in New Zealand, although information regarding this was not readily available due to the small numbers of people expected.</p><h2><em>Impact on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system</em></h2><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there was a lack of evidence to assess the impact of funding food thickeners in the community for people with persistent and progressive swallowing disorders among Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system.</p><h2><em>Background</em></h2><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in February 2023 Pharmac had released a public <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"" style=""color: windowtext;"">consultation on a proposal</a> to phase out the funding of food thickeners\xa0in the community. The Committee noted that the vast majority of the responses received did not support Pharmac’s proposal and requested that access to food thickeners in the community be retained and widened to include people with dysphagia due to causes other than motor neurone disease.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee noted the responses to the consultation. The Committee appreciated and valued the information shared by Motor Neurone Disease NZ regarding the health need and lived experience of people with motor neurone disease in New Zealand and the use of food thickeners to help manage their condition.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the extensive history of clinical advice from PTAC and Pharmac’s Specialist Advisory Committees (previously PTAC Subcommittees) for the use of food thickeners in the community. The Committee noted that PTAC had most recently considered the <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">funding of food thickeners in the community in 2021</a> following the release of a Request For Information by Pharmac.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that two brands of food thickeners were currently funded for use in hospital and in the community for people with dysphagia (swallowing difficulties), with community funding restricted to people with motor neurone disease with a swallowing disorder. The Committee noted that this restricted community funding was inconsistent with clinical practice, as dysphagia can occur in conditions other than motor neurone disease.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the rationale for funding food thickeners in the community for people with motor neurone disease with swallowing disorder (and not funding for other causes of dysphagia/swallowing disorder) is not apparent and appears to have arisen shortly after the establishment of Pharmac.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the inconsistent funding of food thickeners in the community had resulted in a complaint to the Human Rights Commission (HRC) alleging discrimination on the basis of disability. This complaint was on the grounds that food thickeners in the community are currently funded for one group of people with a particular underlying condition, and not for people with different underlying conditions, even though both groups were said to require the product to address the same health need– namely dysphagia.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">2021</a> PTAC had considered a range of information regarding the funding of food thickeners in the community, and that the purpose of the present discussion\xa0was to consider any new information not considered already in 2021, and to consider the responses to the <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">February 2023 consultation</a>.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in 2021 it had also <a href=""https://pharmac.govt.nz/assets/2021-05-20-PTAC-meeting-record-web-version.pdf"" target=""_blank"">confirmed its previous recommendation</a>\xa0that the community funding of food thickeners be delisted from the Pharmaceutical Schedule as there was insufficient evidence that food thickeners would be expected to address the unmet needs and provide clinically meaningful benefits for people with dysphagia. Additionally, the Committee had noted there is some evidence of a risk of harm from use of food thickeners in dysphagia, and it would be difficult to define a specific population that may benefit from food thickeners.</p><h2><em>Health need</em></h2><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there were a large number of conditions that could result in dysphagia. The Committee considered that people with dysphagia could be split into two groups. The first group is people with dysphagia that stabilises or improves over time. The second group experiences persistent and progressive dysphagia that worsens with time, frequently caused by underlying diseases causing lifespans that are time-limited, and leads to significant weight loss and/or dehydration, and the recommendation of surgical interventions such as a percutaneous endoscopic gastrostomy (PEG) to meet nutritional/hydration requirements. The Committee considered that the latter group would have a higher health need than other people with dysphagia. The Committee considered that this group would include people with bulbar and pseudo bulbar palsy, including but not limited to, people with motor neurone disease, people with advanced Parkinson’s disease, people with advanced multiple sclerosis, and people with Huntington’s disease.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the number of people in this group would be small and the majority would be included in the currently eligible group of people with motor neurone disease.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered further work would need to be undertaken by Pharmac staff, including engagement with relevant specialists, to clearly define the group of people with persistent and progressive dysphagia in New Zealand, and to determine whether any widening of access criteria is required to include all people in this group.,.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that coughing and choking while eating and drinking is uncomfortable and distressing for people with persistent and progressive dysphagia, their whānau, and caregivers.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the people with persistent and progressive dysphagia with the highest health need would require feeding via a PEG or other similar surgically placed interventions as their dysphagia worsened. The Committee noted that there would be a subset of this group who are unable to receive a PEG, or similar intervention, due to deteriorating respiratory function and significant perioperative risk. .</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered there was currently a high unmet need for people with persistent and progressive dysphagia, and noted there was often no cure for the underlying cause of their dysphagia and they typically have very short life expectancies. The Committee considered that due to this high unmet health need, even a small improvement in quality of life could have a pressing and meaningful impact.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members discussed whether, the threshold of evidence for ongoing funding in the community of any pharmaceutical might differ from the evidentiary threshold for widening of access of any pharmaceutical to new population groups or funding a novel treatment. Members considered the latter might be expected to better demonstrate evidence of benefit.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that people with motor neurone disease and the clinicians may consider that any removal of funding of food thickeners in the community would increase their health need.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted information from Motor Neurone Disease NZ that due to the rapidly progressive nature of their disease, people with motor neurone disease in New Zealand typically receive food thickeners for a period of 6 months, with a small number of people receiving food thickeners for up to 12 months.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in addition to food thickeners other options are available to help people manage their dysphagia such as using the chin down technique when swallowing, pacing when eating and drinking, posture, and pureed food, however these techniques are unlikely to fully resolve a person’s dysphagia.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that people with dysphagia would typically be cared for by a multidisciplinary team, including Speech Language Therapists who advise on appropriate options including the use of food thickeners.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that video-fluoroscopic swallowing studies (VFSS) are often requested by Speech Language Therapists to establish a diagnosis and demonstrate aspiration. Liquids of different thickness can be evaluated via VSS to determine whether thickening reduces aspiration.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that the thickening of fluids and foods to reduce aspiration would not reduce aspiration occurring outside of eating and drinking.</p><h2><em>Health Benefit</em></h2><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee recalled the evidence it had reviewed as part of its February 2021 consideration of the community funding of food thickeners.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered research that had become available since its February 2021 review of food thickeners, as well as information it had not considered in 2021, including the following:</p><p class=""ql-indent-1"">1.25.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291955/"" target=""_blank"">Steele et al. Breathe 2021;17:210003</a></p><p class=""ql-indent-1"">This review of the evidence for thickened fluids in the management of dysphagia concluded that there is no evidence to support the clinical benefits of thickened fluids in the treatment of dysphagia. In addition, there was some evidence that thickened fluids are a poorly tolerated intervention associated with lower health related quality of life and increased risks of malnutrition and dehydration.</p><p class=""ql-indent-1"">1.25.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28730887/"" target=""_blank"">Kaneoka et al. Clin Rehabil 2017;31:1116-25</a></p><p class=""ql-indent-1"">A systematic review and meta-analysis of published or unpublished randomised controlled trials and prospective non-randomised trials comparing the incidence of pneumonia with intake of thin liquids plus safety strategies vs thickened liquids in adult patients who have previously aspirated on thin liquids. This concluded that amongst patients with a low risk of pneumonia there was no significant difference in the risk of pneumonia in patients who took thin liquids with safety strategies compared with those who took thickened liquids only (odds ratio (OR) 0.82, 95% CI 0.05-13.42, p = 0.89).</p><p class=""ql-indent-1"">1.25.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509132/"" target=""_blank"">Ahn et al. Medicine (Baltimore). 2022;101(38)</a></p><p class=""ql-indent-1"">This observational pilot study investigated the status of thickener use in twenty dysphagia patients with brain lesions and then measured the incidence of adverse events based on fluid viscosity. Forty percent of the cases did not successfully formulate their thickener to correct viscosity, as trained.</p><p class=""ql-indent-1"">1.25.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.frontiersin.org/articles/10.3389/fneur.2017.00094/full"" target=""_blank"">Onesti et al. Front Neurol. 2017; 8:94</a></p><p class=""ql-indent-1"">A retrospective study conducted over a two year period which aimed to investigate the clinical features associated with deteriorated swallow in one hundred forty-five people with amyotrophic lateral sclerosis (ALS) with spinal and bulbar onset and describe the modification of diet and liquid intake. The study concluded that the frequency of use of normal and semi-solid diets decreased over time, while that of pureed diets and PEG prescription increased. Forty-four percent of dysphagic patients refused thickeners or PEG.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of international clinical guidelines on use of thickened fluids for dysphagia post stroke, which the Committee had reviewed in May 2021, which noted 13 clinical guidelines were available and, despite the lack of clinical evidence available the consensus statements were\xa0that thickened fluids were recommended (<a href=""https://onlinelibrary.wiley.com/doi/10.1111/jep.13372"" target=""_blank"">McCurtin et al. J Eval Clin Pract. 2020;26:1744-60</a>)</p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was no new primary research or clinical trial evidence or food thickeners in dysphagia, including dysphagia in motor neurone disease, and that newly published systematic reviews included previously reviewed primary evidence. The Committee considered that there was no new evidence to support the benefits from food thickeners.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Overall, the Committee considered that the evidence available did not support the use of food thickeners for the management of dysphagia.</p><p><span style=""color: black;"">1.29.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted references to the use of food thickeners were included in the <a href=""https://mnd.org.nz/wp-content/uploads/2022/11/NZ-Best-Practice-Recommendations-For-The-Care-Of-People-With-MND-issue-1-November-2022-FINAL.pdf"" target=""_blank"">New Zealand Best Practice Recommendations for people with Motor Neurone Disease</a>, which were produced by Motor Neurone Disease New Zealand.</p><p><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there were a very limited number of high-quality trials that had been undertaken to evaluate the benefit associated with food thickeners and considered that none of these trials reported any benefit associated with the use of food thickeners in the management of dysphagia.</p><p class=""ql-indent-1"">1.30.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that these trials had been undertaken in populations with dysphagia from a range of causes and severities, and none of them included people with motor neurone disease or other similar groups with persistent and progressive dysphagia.</p><p class=""ql-indent-1"">1.30.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In addition, the Committee considered the endpoints investigated in the studies, such as a reduction in aspiration pneumonia and overall improvements in quality of life, may miss a small group of people with dysphagia who are receiving some benefit from the use of food thickeners.</p><p><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the use of food thickeners in the management of dysphagia was an established and long-standing aspect of clinical practice in New Zealand. The Committee noted that any recommendation to remove funded food thickeners from the community would be contrary to international guidelines for the management of dysphagia, noting again however the apparent paucity of clinical evidence supporting guidelines’ recommendations (<a href=""https://onlinelibrary.wiley.com/doi/10.1111/jep.13372"" target=""_blank"">McCurtin et al. 2020</a>).</p><p><span style=""color: black;"">1.32.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was evidence that the inappropriate use of food thickeners could result in harm, including malnourishment or dehydration. The Committee also noted that the ongoing availability of food thickeners in the community could possibly lead to people missing out on the window of opportunity to receive a PEG insertion, resulting in poorer health outcomes. However, the Committee considered any incidence of this would be limited and members were not aware of this arising in clinical practice.</p><h2><em>Suitability </em></h2><p><span style=""color: black;"">1.33.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted feedback received in response to Pharmac’s February 2023 consultation, that the two brands of food thickener funded by Pharmac were not preferred in the management of dysphagia as they are starch based thickeners, which can result in a grainy or lumpy texture, compared to thickeners made from other agents such as xanthan gum or guar gum.</p><p><span style=""color: black;"">1.34.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the thickeners that are currently funded by Pharmac were supplied as a powder and needed to be mixed by the person with dysphagia or their carers, which could make reliably achieving a desired viscosity challenging.</p><p><span style=""color: black;"">1.35.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that some people would not be able to afford other types of preferred thickener and these people were likely to be accessing the currently funded products.</p><p><span style=""color: black;"">1.36.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that premixed, thickened fluids were available, which could avoid the issues with texture and viscosity associated with the currently available thickeners. The Committee was unsure if premixed, thickened fluids would be preferred by people with dysphagia, as they could not be mixed with food or beverages the person already enjoyed.</p><p><span style=""color: black;"">1.37.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that many people with dysphagia who were recommended to use a thickener did not like using them and chose to continue consuming unthickened food and fluids.</p><p><span style=""color: black;"">1.38.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that the ongoing availability of food thickeners in the community could allow for a more individualised approach to be taken to the management of dysphagia than if they were not available.</p><h2><em>Costs and savings </em></h2><p><span style=""color: black;"">1.39.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that, based on current pricing, the per unit cost associated with funded food thickeners was relatively low and would be estimated to cost $364 per person per year assuming 26 cans were used each year.</p><p><span style=""color: black;"">1.40.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that if the access was widened to include all people with dysphagia, the cost to the Combined Pharmaceutical Budget could be substantial.</p><h2><em>General </em></h2><p><span style=""color: black;"">1.41.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee did not consider it would be appropriate to include an assessment by a Speech Language Therapist in any Special Authority criteria for access to food thickeners in the community, because access to Speech Language Therapists was unlikely to be equitable across the country and could present a barrier to access for some people. In addition, it was noted that even if people were able to access a Speech Language Therapist, access to video-fluoroscopic swallowing studies was unlikely to be available to all people in New Zealand.</p><p><span style=""color: black;"">1.42.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was evidence to support the use of PEG feeding in the management of dysphagia, and positive health outcomes associated with this. The Committee considered it would be supportive of greater access to PEG insertions for people with dysphagia. It was noted that this would be dependent on the availability of relevant surgical time and resource which may not be available across regions.</p><p><span style=""color: black;"">1.43.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee reiterated its concerns around the risk of harm from the longer-term use of food thickeners in people without progressive disease.</p><h2><em>Summary for assessment</em></h2><p><span style=""color: black;"">1.44.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for food thickeners if they are to continue to be funded in New Zealand for </span>people with persistent and progressive swallowing disorders, including motor neurone disease.<span style=""color: black;""> This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004AlwX&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000Tnv1"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000003INeAYAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwY2AS'}, 'Id': 'a0POZ000004AlwY2AS', 'Event_Date__c': '2023-11-17', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000005ksiTYAQ'}, 'change': None}]",May 2008,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2013', 'fs': 'Dec 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwN2AS'}, 'Id': 'a0POZ000004AlwN2AS', 'Event_Date__c': '2013-12-05', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2013', 'Status_History__c': 'a132P000000AqYpQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwP2AS'}, 'Id': 'a0POZ000004AlwP2AS', 'Event_Date__c': '2014-05-08', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqgfQAC'}, 'change': None}]",Dec 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2012', 'fs': 'Sep 2012', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwJ2AS'}, 'Id': 'a0POZ000004AlwJ2AS', 'Event_Date__c': '2012-09-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2012', 'Status_History__c': 'a132P000000Aq8HQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2014', 'fs': 'Aug 2014', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwQ2AS'}, 'Id': 'a0POZ000004AlwQ2AS', 'Event_Date__c': '2014-08-29', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Aug 2014', 'Status_History__c': 'a132P000000AqmMQAS'}, 'change': None}]",Sep 2012,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p>Pharmac is seeking feedback on a proposal to stop funding food thickeners for use in the community, following advice from our clinical advisors that there is insufficient evidence to support use of food thickeners and there is some evidence of a risk of harm from their use.\xa0</p>', 'fs': '<p>Pharmac is seeking feedback on a proposal to stop funding food thickeners for use in the community, following advice from our clinical advisors that there is insufficient evidence to support use of food thickeners and there is some evidence of a risk of harm from their use.\xa0</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"">Consultation letter (22 Feb 2023)</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"">Consultation letter (22 Feb 2023)</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004AlwU2AS'}, 'Id': 'a0POZ000004AlwU2AS', 'Event_Date__c': '2023-02-22', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-2-22-proposal-to-phase-out-funding-of-food-thickeners-in-the-community/"" target=""_blank"">Consultation letter (22 Feb 2023)</a></p>', 'Summary__c': '<p>Pharmac is seeking feedback on a proposal to stop funding food thickeners for use in the community, following advice from our clinical advisors that there is insufficient evidence to support use of food thickeners and there is some evidence of a risk of harm from their use.\xa0</p>', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDTaQAO'}, 'change': None}]",Feb 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
